Preventing opioid overdoses in Europe:a critical assessment of known risk factors and preventative measures by Frisher, Martin et al.
                                                              
University of Dundee
Preventing opioid overdoses in Europe
Frisher, Martin; Baldacchino, Alex; Crome, Ilana; Bloor, Roger
Publication date:
2012
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Frisher, M., Baldacchino, A., Crome, I., & Bloor, R. (2012). Preventing opioid overdoses in Europe: a critical
assessment of known risk factors and preventative measures. Lisbon: EMCDDA.
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 16. Mar. 2016
1 
 
 
 
 
Prevalence, Consequences and Data Management Unit 
 
 
 
 
 
 
Preventing opioid overdoses in Europe:  
A critical assessment of known risk factors and 
preventative measures 
 
 
 
 
 
Final report 
 
Martin Frisher (1), Alex Baldacchino (2)  
Ilana Crome (3), Roger Bloor (3)  
 
 
(1) School of Pharmacy, Keele University, UK  
(2) Centre for Addiction Research & Education Scotland, University of 
Dundee, UK 
(3) Academic Psychiatry Unit, Keele University, UK 
 
 
 
October 2012 
2 
Contents 
 
Introductory note......................................................................................................................3 
Summary ..................................................................................................................................4 
1. Introduction ..........................................................................................................................6 
2. Overdose prevention: recommendations, actions and barriers.................................19 
3. Discussion..........................................................................................................................24 
4. Recommendations............................................................................................................26 
5. References.........................................................................................................................33 
6. Appendix 1: Analysis of overdose papers.....................................................................37 
7. Appendix 2. Protocol and Creation of the Drug Deaths Database in Fife ...............55 
8. Appendix 3. A Case Vignette of a Typical Drug Death Victim in Fife 2009.............81 
 
Tables 
Table 1. Measure to reduce road traffic accidents (RTAs)...............................................8 
Table 2. Safety ratio of drugs (assuming no build-up of tolerance) ..............................12 
Table 3. Risk factors classified into three levels: Individual, observers and 
organisational.........................................................................................................................17 
Table 4. Protective factors classified into three levels: individual, observers and 
organisational.........................................................................................................................18 
Table 5. Stages in the cycle of overdose management ..................................................25 
Table 6. Overdose prevention: recommendations, barriers and expert assessment.26 
 
Figures 
Figure 1. People killed in road accidents (European Union, 27 countries) ....................8 
Figure 2. Number of ‘drug-induced deaths’ recorded in EU Member States 
according to national definitions .........................................................................................10 
Figure 3. Top five reasons cited for a personal opiate overdose in a qualitative study 
of 44 Scottish drug users .....................................................................................................14 
Figure 4. Inappropriate intervention reported by bystanders witnessing an overdose 
in a qualitative study of 44 Scottish drug users ................................................................15 
Figure 5. Appropriate intervention of bystanders witnessing an overdose in a 
qualitative study of 44 Scottish drug users .......................................................................15 
Figure 6. Mortality following methadone treatment — discharge status of 110 
patients....................................................................................................................................16 
Figure 7. Factors affecting a bystander’s decision to summon emergency services 
following witness of an overdose in a qualitative study of 61 Scottish drug users .....21 
Figure 8. Why bystanders delay calling an ambulance according the emergency 
service workers......................................................................................................................23 
 
 
3 
Introductory note 
 
This report is the outcome of a project into opioid overdoses. The remit was to focus on 
finding practical methods of overdose prevention. In order to fulfil this remit, a critical review 
of existing knowledge on overdose prevention was conducted. The report adds value to 
existing information by developing a methodology to classify and analyse risk and protective 
factors stratified by those involved (drug users, observers and organisations). The report 
then assesses the extent to which risk and protective factors can be potentially modified at 
different levels, e.g. individual, treatment setting, organisational and strategic. The report 
therefore has the potential to be updated as new information emerges. 
 
As a result of the review, we have attempted to draw out practical measures and 
interventions that could reduce the likelihood of overdose being fatal, especially within the 
European context. In addition, we had the opportunity to filter the findings of the review 
through a Scottish expert group. The group included a wide range of professional groups 
who had day-to-day frontline experience of managing drug misusers and overdose.  
 
There are limitations which should be noted. This was not a comprehensive or systematic 
review (these may be found elsewhere). The studies we considered took place in relatively 
few countries, e.g. UK, Australia, North America. The expert group was ad-hoc and 
geographically specific; other groups might have come to different conclusions.  
 
The views expressed in the report are those of the authors and do not necessarily reflect 
those of the EMCDDA. 
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Summary 
 
Introduction 
 
The objective of this report is to review the literature on preventable risks of fatal overdose 
in heroin users.  To the extent that such factors can be identified, prevention and treatment 
interventions for potentially fatal overdoses can be informed by research findings. Extant 
reports already make a range of recommendations regarding overdose with one review 
stating that ‘most overdoses and deaths are avoidable’.  However, what ‘avoidable’ means 
in this context is unclear. Broadly speaking, the current state of knowledge is that the more 
individual, situational and organisational risk factors that are present, the greater the 
likelihood that the overdose will be fatal. The degree to which this complex set of factors can 
be modified in order to reduce fatal overdose is the focus of this report. 
 
Method 
 
There were four steps. 1. Key reviews were identified (see Appendix 1). 2. Using these 
reviews, the aim was to identify risk/protective factors associated with non-fatal and fatal 
overdoses. 3. The analysis focused on assessing the impact of non-fatal overdoses on 
subsequent overdose experience and differentiating fatal and non-fatal opiate overdoses. 4. 
The information was reviewed by an expert panel at St Andrews University, Scotland in April 
2010.The panel considered the efficacy and feasibility of sixteen measures identified by the 
review. 
 
Key results 
 
The single most important factor for fatal overdose appears to be using other depressant 
drugs at the same time as illicit opiates. It has previously been suggested that some 
multifaceted combination of treatment options, e.g. increasing and improving treatment with 
opiate substitutes, community peer education, family support groups, supervised injecting 
facilities, and making naloxone available at home may be needed to have any practical 
effect on mortality from overdose. However, the review identified barriers at several levels; 
firstly, for drug users themselves, secondly for witnesses, thirdly for service providers and 
fourthly for society.  These barriers need to be overcome in order to reduce overdose. 
Ultimately, without behavioural change on the part of drug users, there is unlikely to be a 
significant reduction in the level of fatal overdose. The expert panel also highlighted the fact 
that overdose is often a symptom of deeper underlying problems in the individual that 
initiate and exacerbate problematic drug use. Without addressing these problems (e.g. 
psychiatric conditions, combinations of depressant drugs), the impact of primary overdose 
prevention may be limited. The panel felt that practical interventions could occur in settings 
not identified in the literature, for example, when drug users are in police custody. However, 
there is no current evidence that such interventions do actually reduce fatal overdose. 
 
In summary, there are many reasons for fatal overdoses and the review did not identify any 
particular measure that is likely to have a significant impact. Rather there is evidence that 
many interventions may reduce overdose, particularly in settings where the drug user is in 
contact with treatment or emergency services. However, it is important to bear in mind the 
distinction between overdose prevention at the clinical and at the population level. At the 
clinical level, specific interventions are available and have been shown to be effective (e.g. 
pharmacological treatment). At the population level, where many drug users are not in 
contact with services, overdose reduction depends on behavioural change by drug users 
themselves (e.g. avoiding the mixture of opiates and other depressant drugs). Overdose 
5 
prevention is a multifaceted problem. Purely technological interventions were thought likely 
to have a relatively limited impact. Rather, overdose involves personal and societal issues; 
only when these are addressed is the level of fatal overdose in Europe likely to decrease. 
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Review of preventable risks of fatal overdose in heroin users 
 
1. Introduction 
 
There have been several reviews on the nature and extent of drug overdoses (Best et al., 
2000; 2001; Rome et al., 2008). These reviews have also sought to identify preventive 
measures that could reduce overdoses. A key issue that has been addressed is the nature 
and extent of factors that differentiate between non-fatal and fatal overdoses. To the extent 
that such factors can be identified, prevention and treatment of potentially fatal overdoses 
can be informed by research findings. 
 
Reviews have focused on four sets of factors. The first set deals with the characteristics of 
the drug users themselves. The second deals with the circumstances in which the overdose 
occurred. The third deals with treatment interventions. The fourth deals with organisational 
response in the aftermath of an overdose. 
 
The reviews make it clear that there are many interacting factors that determine whether or 
not an overdose will be non-fatal or fatal. While there are parameters associated with both 
non-fatal and fatal overdoses, for practical purposes interventions are focused on (a) 
overdose prevention (including opportunities for treatment) and (b) responses to overdose 
that have occurred. 
 
Some responses are obvious, for example, if an overdose has occurred ensuring that 
bystanders take measures on the spot in terms of getting expert help. This might sound 
‘obvious’, but there are barriers, e.g. knowledge of appropriate responses, fear of calling 
emergency services, bystanders’ own state of intoxication. These factors highlight an 
important aspect of overdose that is sometimes forgotten or not acknowledged, namely that 
the act of drug taking is an event with its own set of rules.  While the majority of drugs users 
engage in harm reduction in relation to HIV infection, it is unclear whether they are also 
willing to do so in relation to overdose. An important factor is the trade-off being the specific 
harm reduction measure and the (‘cost’) and the anticipated benefit. In relation to HIV 
infection, there is little cost in using clean injecting equipment (e.g. avoid sharing drugs), 
whereas the perceived cost of harm reduction measures, e.g. not mixing drugs, continuing 
high levels of drug use, for overdose may be higher. While there is evidence that drug users 
have engaged in some harm reduction in relation to overdose, it is difficult to quantify what 
effect this has had on reducing fatal overdoses. 
 
Extant reports already make a range of recommendations regarding overdose. However, 
the circumstances (individual, social and cultural) often mean that recommendations cannot 
be implemented or are not relevant in certain settings. 
 
One issue is whether overdose prevention should be equated with, say, heart attack 
prevention, where it is assumed that a ‘rational’ person would want to reduce the risk by 
taking appropriate measures. Many people who overdose have already done so on previous 
occasions. Thus, in some instances, previous overdoses do not appear to prevent further 
risky use. 
 
Another issue is the setting and circumstances of overdose studies. How legitimate is it to 
extrapolate general conclusions from a study of overdose in one setting to different 
settings? Once again, a parallel with heart attack is useful. It is considered scientifically 
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valid, for example, to compare the results of different studies that have examined the role of 
aspirin in reducing heart attack. These studies are carefully controlled.  In contrast, it is 
rarely possible to conduct controlled studies of overdose, which are primarily observational 
in nature. An exception is the current NALoxone InVEstigation (N-ALIVE) Pilot Randomised 
Controlled Trial (RCT). The hypothesis of the main trial is that giving naloxone on release to 
prisoners with a history of heroin use by injection will reduce heroin overdose deaths in this 
population by 28 % in the first 12 weeks after release. Factors that appear to be important in 
one study of overdose, say in Australia, may have different relevance in other countries, 
where drug use patterns and responses to overdose may be very different. This may be 
partly due to cultural factors and partly due to differences in study design, populations and 
outcomes. 
 
It is important to bear in mind that every drug-taking event involves a complex set of factors, 
including: 
 
 Which drug or combinations of illicit, licit and prescription drugs were taken 
and by what route of administration? 
 How much? How frequently? How pure was the drug? 
 What was the person’s tolerance? 
 Had the person recently been released from prison? 
 Where did the overdose take place? 
 Did the person have a history of psychiatric problems? 
 Did the person have physical health problems? 
 Had the person engaged with drug treatment and if so what were the 
outcomes? 
 Use of other depressant drugs at the same time (alcohol and 
benzodiazepines are the major drugs) 
 Age/duration of drug use 
 Gender 
 
When a drug overdose occurs, it is as a consequence of one or more of these (and perhaps 
other) factors. There is a spectrum along which overdoses lie, ranging from not feeling well 
through to fatality. It has already been noted that: 
 
‘although there are clearly individual risk factors…and situational risks our 
ability to categorise and predict fatality remains poor’ (Petersen & Best, 2005). 
 
‘While significant risk factors for opioid overdose fatality are well recognised, the 
mechanism of fatal overdose remains unclear’ (Warner-Smith et al., 2001). 
 
Thus, the severity of the overdose can only be predicted in probabilistic terms. Broadly 
speaking, the current state of knowledge is that the more individual, situational and 
organisational risk factors that are present, the greater the likelihood that the overdose will 
be fatal. A parallel may be drawn with road traffic accidents (RTAs) whereby multiple 
methods (see Table 1) have resulted in reduction in the rate of RTAs (Charlton and Smith, 
2003).  
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Table 1. Measure to reduce road traffic accidents (RTAs) 
 
1. Use seat belts. 
2. Enforcement of speed limits. 
3. Prohibition of alcohol in excess of legal use while driving. 
4. Prompt medical attention when an RTA occurs. 
5. Put speed bumps along intersections. Drivers will be forced to reduce speed 
rather than speed up to beat a changing stoplight. Speeding through 
intersections and running red lights are among the biggest cause of traffic 
accidents. 
6. Zebra crossings should be provided for pedestrians for safe road crossings at 
appropriate places. 
7. Signals for road crossings at important busy places where a large number of 
people have to cross the road everyday. 
8. Road Safety Day/Road Safety Week in schools. 
 
Figure 1 shows that the number of people killed in road accidents in Europe has been 
gradually declining since 1996. 
 
Figure 1. People killed in road accidents (European Union, 27 countries)  
 
 
Source: http://epp.eurostat.ec.europa.eu.  
 
 
The key issue for this report is whether an analogous set of preventive measures for 
overdose can be identified and evaluated. 
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1.1 Policy relevance 
 
Drug-related deaths are a major cause of mortality in Europe, particularly among people 
aged 15–49. One study found that 10 % and 23 % in this age group could be attributed to 
opioid use (Bargagli et al., 2005). During the period 1990–2006, between 6 400 and 8 500 
drug-induced deaths were reported each year by EU Member States, Croatia, Norway and 
Turkey, adding up to more than 135 000 deaths. In 2006, the United Kingdom and Germany 
accounted for half of all reported deaths (EMCDDA, 2009). There appears to be a paradox 
in that levels of injecting drug use have been decreasing while the number of drug users in 
contact with treatment services has been increasing. The EMCDDA has considered a range 
of factors, including an ageing population becoming more vulnerable; increased levels of 
polydrug use; a failure of existing services to target or reach those most vulnerable; or even 
an increase in the numbers of relapsing opioid users leaving prison or treatment, who are 
known to be at particularly high risk (EMCDDA, 2009). 
 
Figures on drug-related deaths are difficult to interpret (EMCDDA, 2009b). Figure 2 shows 
the fluctuating trends in drug related deaths. Thus, it is difficult to establish whether 
preventative measures have had any impact.  Between 2000 and 2003, most EU Member 
States reported a decrease followed by a subsequent increase in deaths between 2003 and 
2008. Preliminary data available for 2009 suggest an overall figure equal to or slightly below 
that for 2008 (EMCDDA, 2011a, Vicente, 2010). The reasons for the sustained numbers of 
reported drug-induced deaths are difficult to explain, especially given the indications of 
decreases in injecting drug use and increases in the numbers of opioid users in contact with 
treatment and harm reduction services. Against this possible reduction in drug use in the at-
risk population, stable or rising numbers of drug-induced deaths have become a major 
cause of concern.  
 
A number of mortality cohort studies are currently underway in Europe (EMCDDA, 2011b, 
Giraudon, 2011). This type of study can determine overall and cause-specific mortality rates 
for the cohort, and can estimate the group’s excess mortality compared to the general 
population. Large-scale longitudinal cohort studies can be used to test hypotheses, for 
example, about the reasons for changes in the numbers of drug-induced deaths, as well as 
to monitor the overall risk and detect changing patterns in the causes of death. 
Unfortunately, some countries show a low detection rate of overdose in the general mortality 
registries and, therefore, a significant proportion of deaths recorded with an ‘unknown’ or an 
insufficiently specified cause (e.g. cardiac arrest) might be overdoses (EMCDDA, 2009).  
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Figure 2. Number of ‘drug-induced deaths’ recorded in EU Member States 
according to national definitions  
 
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
 
Source: http://www.emcdda.europa.eu/stats11/drdtab2e 
 
 
1.2 Scope of the review 
 
It was agreed that this would be a descriptive process, whereby the existing reviews would 
be synthesised and gaps in the literature identified. As a result of this process, 
recommendations for practice and policy might be outlined. It is, however, beyond the scope 
of this review to critically appraise all the individual studies on overdose. Furthermore, the 
review does not detail the complexities of factors in different countries that might operate to 
prevent or increase fatal overdose (such as the legal framework, accessibility to services, 
professional attitudes, resources and demands, quality of services, the demographics of the 
population, availability of different drugs). 
 
The project objectives were to: 
1. Undertake a review of the literature. This is based on the references listed in 
section 6 (Appendix 1). 
2. Focus (where information is available) on the following key areas: 
a. Poly-substance misuse and injection; 
b. Comorbid disorders including suicide, mental and physical health; 
c. Care pathways including treatment (e.g. prescribing, interactions between 
illicit drugs and prescribed medications, methadone) and service models (e.g. 
detoxification, substitution, drop-outs); 
d. Special groups, e.g. adolescents, prisoners (in particular, after prison 
release), pregnant drug users, and older people.  
3. Focus on both fatal and non-fatal opiate overdoses. The topics covered 
include (again where information is available): 
a. Assessment of impact of non-fatal overdose on subsequent overdose. 
b. Differentiate between fatal and non-fatal opiate overdose.  
c. Assessment of morbidity/consequences related to non-fatal overdose. 
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1.3 Method 
 
Key reviews were identified (see Appendix 1). Reviews published from 2000 to 2008 in 
Europe, Australia and the USA were included. For this project, the aim was to identify 
risk/protective factors associated with non-fatal and fatal overdoses. With a few exceptions, 
we did not go back to source papers. Therefore, studies were considered only in terms of 
the information presented in the reviews. A total of 31 papers were analysed for this report. 
 
For each study, presented in these reviews, the following dimensions were categorised: 
 
1. Prevention and treatment intervention, organisational response or other 
activities related to overdose. 
2. Did the intervention/activity increase or decrease the likelihood of fatal 
overdose? 
3. Study population e.g. treatment settings (e.g. recent prison release, drug 
injectors). 
4. Defined outcome, e.g. non-fatal or fatal overdose. 
5. Comments, e.g. clarifying an aspect of the study. 
6. Country where the study was conducted. 
 
 
1.4 Definitions 
 
Overdose 
 
The EMCDDA definition of drug-related deaths (more precisely, drug-induced deaths) 
includes ‘people who die directly due to use of illegal substances, although these often 
occur in combination with other substances, such as alcohol or psychoactive medicines. 
These deaths occur generally shortly after the consumption of the substance’. 
(http://www.emcdda.europa.eu/themes/key-indicators/drd) (EMCDDA, 2010). They are also 
known as overdoses or poisonings.  For the purpose of this review and because evidence of 
8/10 reported cases of drug-induced deaths reported to the EMCDDA being related to 
opiates, mainly heroin, we consider only opiate overdoses. The review does not cover 
overdoses related only to alcohol, overdoses related only to prescription drugs, or only to 
non-opioid drugs. 
 
The International Classification of Diseases (ICD) is the international standard diagnostic 
classification for all general epidemiological and many health management purposes and 
clinical use (World Health Organization, 1992). 
http://apps.who.int/classifications/apps/icd/icd10online/). The current edition (ICD-10) 
classifies overdoses in Chapter XIX: Injury, poisoning and certain other consequences of 
external causes (S00-T98). It has been noted that, ‘the lack of more specific codes in both 
the ICD-9 and the ICD-10 precludes perfect correspondence between unintentional heroin 
overdose deaths and a specific code’ (Landen et al., 2003).  
 
(Sporer, 1999) discusses the complex clinical issues surrounding drug overdose. In their 
qualitative study of overdose, (Rome et al., 2008) defined an overdose as ‘a situation where 
after using, you or another person passed out and couldn’t wake up’. In essence, overdose 
may be defined by clinical or self-report criteria. 
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Safety (or lethal) ratio assuming no tolerance 
 
The safety ratio equals the number of standard or usual doses it takes to reach the median 
lethal dose (Caulkins & Menefee, 2009). The median lethal dose is the dose required to kill 
half the members of a tested population, thus, half of a population who consumed six times 
the average dose of heroin would die. This assumes that the person has not built up 
tolerance to the drug.  The range of safety ratios of abused drugs is wide (Leung, 2007). 
Table 2 shows some of the safety ratios given by Leung (2007). 
 
Table 2. Safety ratio of drugs (assuming no build-up of tolerance) 
 
Source: Leung (2007). 
 
Table 2 shows that heroin has the lowest safety ratio. This means that a person with normal 
tolerance would have to take only six times the usual ‘effective’ dose to have a 50 % chance 
of fatality. 
 
To put the information about overdose in perspective, the following key points were 
extracted from the literature review. However, many of these facts may be context-specific 
and not generalisable to other settings; also, some of these points are the cited authors’ 
interpretation of their findings.   
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1.5 Drug users 
 
•   About 2 % of people who inject heroin die each year, which is six to 20 times 
the rate expected in peer controls who do not use drugs (Sporer, 2003). 
•   In persons who regularly inject heroin, half of these deaths are attributable to 
overdose (Sporer, 2003). 
•   On average, heroin users who overdose report having experienced three 
overdoses, (mean 3.26, range 1–20) (Rome et al., 2008). 
•   Most experience overdose only once every few years, but a minority do so 
far more often (Best et al., 2000) but see also (Rome et al., 2008). 
•   ‘Experience of overdose is neither a deterrent to future drug use nor a 
motivator for seeking treatment’ (Zador, 2005, p. 7).  
•   Most users believed that the main reason for overdose was the quantity or 
strength of the heroin (McGregor et al., 1998). 
•   Few deaths occur ‘instantaneously’ (Sporer, 1999) but see (Lenton & 
Hargreaves, 2000). 
•   Instant death occurs in approximately 15 % of overdose cases (Lenton & 
Hargreaves, 2000). 
•   Epidemiology of non-fatal overdoses is quite similar to that of fatal overdoses 
(Sporer, 2003). 
•   41 % of morphine positive deaths had morphine values below the ‘fatal’ level 
of 0.15 mg/L and 29 % of methadone-positive deaths had methadone values 
below the ‘fatal’ level of 0.2 mg/L (Zador, 2005).  
•   Of the 77 resuscitated heroin users in two Scottish accident and emergency 
departments, suicidal thoughts or feelings before overdosing was the 
underlying reason for the overdose in 49 % (Neale, 2000).  
•   Suicide and accidental drug overdose seemed to be less of a dichotomy and 
more a spectrum of intention (Zador, 2005). 
•   80 % of survivors of heroin overdose did not perceive themselves to be at 
high risk of overdose, despite experiencing one in the previous six months 
(Darke & Ross, 1997). 
 
Research commissioned by the Scottish Government sought the views of people who had 
directly or indirectly experienced an opiate overdose (Rome et al., 2008). Just under half of 
the participants had experienced a personal overdose. Figure 3 shows the top five 
perceived causes of a personal overdose. 
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Figure 3. Top five reasons cited for a personal opiate overdose in a qualitative study 
of 44 Scottish drug users   
 
 
Source: Rome et al., 2008. 
 
1.6 Witnesses and bystanders 
 
•   Heroin users who witness an overdose are usually intoxicated themselves 
(Darke et al., 1996). 
•   Inflicting physical pain was the most common intervention used by injecting 
drug users to revive an overdose survivor (Zador, 2005).  
•   Less than half tried cardiopulmonary resuscitation (CPR) and in most cases 
death had occurred by the time the ambulance arrived (Zador, 2005).  
•   In one in four of the cases where there was at least one witness reported as 
being present, and the death was not reported as instantaneous, a different 
outcome could have occurred if the witness had acted more swiftly, 
commenced CPR and called an ambulance at the first sign of trouble 
(Hickman et al., 2007).  
•   Approximately 60 % of deaths occur in the company of others (Lenton & 
Hargreaves, 2000). 
•   Overdose witnesses only call an ambulance in about 10 % of cases (Rome et 
al., 2008). 
 
 
The Scottish Government report (Rome et al., 2008) also interviewed witnesses to an 
overdose. The report found that a range of interventions, classified by the authors as 
‘inappropriate’ and ‘appropriate’ (Figure 5) were taken.  
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Figure 4 Inappropriate intervention reported by bystanders witnessing an 
overdose in a qualitative study of 44 Scottish drug users  
 
 
Source: Rome et al., 2008. 
 
 
 
Figure 5 Appropriate intervention of bystanders witnessing an overdose in a 
qualitative study of 44 Scottish drug users  
 
 
Source: Rome et al., 2008. 
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1.7 Organisational response to drug users 
 
•     Prior to discharge from hospital, overdose patients are not routinely given 
information about overdose prevention (Rome et al., 2008).  
•     Case records of people who have died from a drug-related death provide 
histories of multiple overdoses and hospital attendance prior to death (Zador, 
2005). 
•     Zanis and Woody (1998) undertook a study of one-year mortality rates 
following methadone treatment discharge and found that death rates, 
especially overdose, are high among patients who are unfavourably 
discharged, or who drop out of methadone treatment. 
•     Bird and Hutchinson, S. (2003) studied the two weeks after release from 
prison compared to other times of liberty. They found that drug-related 
mortality was seven times higher in the first two weeks of liberty than at other 
times. In England, it has been estimated that 15 % of the 1 506 drug 
overdose deaths in 2005 occurred in people recently released from prison 
(Department of Health, 2007). 
 
Figure 6. Mortality following methadone treatment — discharge status of 110 patients 
 
 
Source: Zanis & Woody, 1998. 
 
 
1.8 Classification of risk factors 
 
The studies described in the reviews were tabulated as described above and the results are 
shown in Appendix 1. From these tables, lists of risk and protective factors for non-fatal and 
fatal overdose were drawn up (Tables 3 and 4).  It should be noted that the description of 
the factors is brief and on some occasions, its inclusion as risk or protection may not be 
obvious. For example, ‘immediate overdose onset’ is considered to be a protective factor 
(Best et al., 2001) because rapid overdoses are more likely to result in witnesses 
intervening. 
17 
 
Table 3. Risk factors classified into three levels: Individual, observers and 
organisational 
Risk factors 
Individual Observers Organisational 
Drug use 
• Topping up on a legitimate methadone prescription 
• Using someone else’s methadone prescription 
• Preferring illegal drug use in favour of prescribed 
methadone 
• Not always taking prescribed medication, which may 
reduce drug tolerance and increase withdrawals and 
susceptibility to overdose 
• Unintentionally taking too many drugs, due to 
unexpected heroin purity, lower tolerance, or 
ingesting unknown tablets 
• More frequent use of illicit methadone  
• Very high levels of drug intake with users 
experiencing difficulty in controlling their drug intake 
• High levels of polydrug use and prescription drug 
use 
• Reduced tolerance to opioids 
• Benzodiazepine use 
• Large quantities of alcohol 
• Injecting cocaine 
• Length of time that people have used drugs 
• Sporadic use of heroin 
Circumstances of overdose 
• Slow overdose onset 
• Two weeks after release from prison (compared to 
other times of liberty) 
Experience of treatment 
• Withdrawal from drug treatment 
• Leaving treatment 
• Periods of induction and transition, such as when 
drug users (re)enter or discontinue treatment 
• Greater number of separate treatment episodes 
Psychiatric/physical 
• Suicidal ideation 
• History of mental health problems, a current 
psychiatric diagnosis and prescription of 
psychotropic medicines 
• Access to antidepressants, through genuine 
prescriptions, obtaining different antidepressants 
from different prescribers 
• Feelings of indifference and carelessness 
• High levels of hepatitis and cirrhosis 
Social 
• More drug injectors in the social network 
experiencing conflict with more network members 
• Life events: recently experienced bereavement of 
someone close to them, a relationship breakdown, 
accommodation problems 
Circumstances 
• Injecting drug use in public places affords less 
opportunity to test the sample strength 
Consequences of 
intervening 
• Presence of 
bystanders, e.g. 
fear of police 
involvement 
• Fear of social 
repercussions  
 
Treatment  
• Unable to access a methadone 
prescription 
• Unable to obtain substitute 
medication 
• Strict rules (for methadone 
programmes) increasing the risk 
of discharge resulting in a high 
mortality rate 
• Take-home Naloxone (THN) 
• Methadone dose is increased too 
quickly, or initial dose is too high 
• Poor treatment response 
• Increasing use of multiple 
doctors 
• Excessive increases in 
psychoactive drug prescriptions 
 
Emergency services 
• Changes in police activity, 
whereby dealing and use at 
static sites, such as houses, is 
displaced to street dealing in 
other areas 
 
 
Prison release 
• Decreased tolerance 
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Table 4. Protective factors classified into three levels: individual, observers and 
organisational 
Protective 
Individual Observers Organisational 
Circumstances of overdose 
• Immediate overdose onset 
• Methadone maintenance — 
daily dose between 60 mg and 
120 mg 
 
Experience of treatment 
• Engaged in treatment 
 
Availability of prescribed drugs 
• Availability of buprenorphine in 
treatment settings 
 
Experience of overdose 
• Past witnesses of a fatal 
overdose 
• Witnesses had received 
information on how to 
prevent overdose/revive a 
casualty 
 
Reaction to overdose 
• Witnesses present at an 
overdose event are 
willing to intervene 
• Witnesses remaining with 
the casualty 
• Witnesses who attempted 
CPR 
• Public intervened to help 
overdosed or 
unconscious drug users 
 
After calling an ambulance 
• Ensured still breathing 
and place person in the 
recovery position  
• Cleared space around the 
unconscious person for 
the ambulance crew to 
work on arrival 
• If in a communal building, 
limited the number of 
non-essential persons at 
the scene 
• Stayed at the scene to 
provide essential 
information to ambulance 
staff  
Emergency services 
• Mapping high risk areas and 
identifying those repeatedly 
overdosing 
• Reducing police attendance at 
the scene of an overdose and 
decreasing the risk of arrest 
• Ensuring that police officers do 
not routinely attend ambulance 
call-outs to drug overdoses, 
unless a death has already 
occurred 
• Role of emergency service 
operators  
• Emergency units to provide 
contact and advice cards to 
known drug users following an 
overdose  
 
Health services 
• Periods of hospitalisation can 
provide an opportunity for 
appropriate interventions to be 
targeted at these high-risk 
patients 
• Substance use specialist nurses 
within the accident and 
emergency department to 
progress referral for drug 
overdose casualties 
• Increasing the availability of 
treatment among heroin users, 
both in the community and in 
prison 
• THN (Take-home Naloxone) 
• Safer injecting rooms (SIRs) 
 
Prison services  
• Thorough care for drug users to 
make the post-release period 
less of an overdose hotspot  
 
 
 
 
19 
2 Overdose prevention: recommendations, actions and barriers  
 
This section re-organises the material from the literature review into a more accessible form. 
The Frequently Asked Questions (FAQ) includes topics that the review was mandated to 
examine.  
 
2.1 What perception do drug injectors have of the risk of overdose? 
•     Experience of overdose is neither a deterrent to future drug use nor a 
motivator for seeking treatment (Zador et al., 2005). 
•     Most users believed that the main reason for overdose was the quantity or 
strength of the heroin (McGregor et al., 1998). 
•     80 % of survivors of heroin overdose did not perceive themselves to be at 
high risk of overdose (Darke & Ross, 1997).  
•     When they were asked why they thought they had survived their most recent 
overdose, by far the most common response (n=25) was that someone else 
had been present at the time (Zador, 2005). 
•     There is a notion within the drug-using population that an overdose is an 
‘occupational hazard’ (Independent Working Group on Drug Consumption 
Rooms, 2006). 
•     In Scotland, overdose survivors cite recent release from prison as the main 
risk factor (Rome, 2008). 
 
2.2 What proportion of drug injectors have had a non-fatal overdose? 
•     Most experience overdose only once every few years, but a minority do so 
far more often (Best et al., 2000).  
•     Of active injecting heroin users, 23–33 % had a non-fatal overdose in the 
past year (Sporer, 2003). This seems to conflict with the findings of Best et 
al., 2000. 
•    Approximately half report a history of non-fatal overdose (Kerr et al., 2007). 
 
2.3 What measures do drug injectors take to reduce the risk of overdose? 
•    Inject with someone present (Zador, 2005). 
•    Measures suggested by drug users include safer injecting facilities, 
information videos, legalisation of heroin and resuscitation classes (Zador, 
2005). 
 
2.4 What is the drug injectors’ experience of witnessing an overdose? 
•     43 % have witnessed a heroin overdose in another user within the last year 
(Sporer, 2003).  
•     Heroin users who witness an overdose are usually intoxicated themselves 
(Darke et al., 1996).  
•     Fatal overdoses were witnessed by 55 of 312 injecting drug misusers — 
18 % of the total sample and 33 % of those who had witnessed an overdose 
(Williamson & Gossop, 1999). 
•     Fourteen percent of those who had witnessed an overdose in the past year 
reported that the outcome was death (Davidson et al., 2002). 
 
2.5 What proportion of drug injectors have intervened when witnessing an 
overdose? 
•     Inflicting physical pain was the most common intervention used by injecting  
drug users to revive someone who had overdosed (Zador, 2005). 
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•     Less than half had tried CPR and in most cases death had occurred by the 
time the ambulance arrived (Zador, 2005). 
•     Drug users who survive an overdose and go on to witness others having an 
overdose are less likely to intervene (Tobin et al., 2007). 
 
2.6 What practical recommendations are there for overdose reduction? 
•     The Scottish review (Rome et al., 2008) made the following 
recommendations: 
— improve the quality of existing responses to overdose incidents (police and 
ambulance); 
— improve the assessment of needs; 
 — improve and extend current care provision for drug users;  
— information and training for emergency service staff; 
— information and training for drug users and significant others.  
•     Ways to reduce the damage include increasing access to treatment, 
developing Naloxone interventions for when overdoses do occur, and offering 
anti-overdose training to addicts in treatment and out of treatment (Best et 
al., 2001). 
•     Some combination of increasing treatment with opiate substitutes, community 
peer education, family support groups, supervised injecting facilities, and 
making Naloxone available at home may be needed to have any practical 
effect on mortality from overdose (Sporer, 2003).  
•     Interventions that provide drug treatment information and enhance motivation 
for treatment in the medical setting are recommended, as are policies that 
reduce barriers to treatment entry among motivated drug users (Pollini et al., 
2006). 
 
2.7 What are the main underlying reasons for overdose? 
•     In 2003 in Scotland, most fatal overdoses (68 % of cases) were accidental, 
while 13 % were classed as suicides (Zador, 2005).  
•     Neale (2000) interviewed 77 resuscitated heroin users in two Scottish 
accident and emergency departments and found that 38 respondents (49 %) 
reported suicidal thoughts or feelings before overdosing.  
•     In contrast, deliberate heroin overdose as a method for attempting suicide 
was reported by only 10 % (Darke & Ross, 2001). 
•     In another Australian study, a substantial minority (17 %) of the sample 
indicated that they had ever taken an intentional overdose, and 67 % had 
had one within the last six months (11 % of the total sample) (Heale et al., 
2003). 
 
2.8 Why are bystanders both a risk factor and a protective factor? 
•     Risk factors: 
— inappropriate intervention when witnessing an overdose; 
— bystanders are often users themselves and their own state of consciousness 
is affected; 
— fear of the repercussions of contacting the emergency services; 
— presence of other bystanders likely to decrease the probability of calling an  
ambulance; 
— delay in summoning help for fear of possible repercussions, particularly if 
children are in the house.  
•     Protective factors: 
21 
— witnesses present at an overdose event are willing to intervene, for example, 
with CPR; 
— witnesses are likely to call emergency services.  
 
Figure 7 shows that fear of prosecution prevents 93 % of a sample of drug users from 
summoning help after witnessing an overdose. However, 31 % would call for help if they felt 
sure that there was no police involvement. 
 
 
Figure 7. Factors affecting a bystander’s decision to summon emergency services 
following witness of an overdose in a qualitative study of 61 Scottish 
drug users  
 
 
Source: Rome et al., 2008. 
 
2.9 What aspects of polysubstance misuse contribute to fatal overdose? 
•     Concurrent use of benzodiazepines (Stewart et al., 2002). 
•     Concurrent use of alcohol, especially heavy drinking (McGregor, C., Darke, 
S., Ali, R. et al., 1998). 
•     Longer duration of injecting (Bartu et al., 2004). 
•     Intermittent injecting (Oliver, P. & Keen, J., 2003). 
•     Additional psychoactive prescriptions perhaps due to mental health issues 
(Oyefeso, A., Valmana, A., Clancy, C. et al,. 2000). 
•     ‘Top up’ opiate in addition to prescriptions (Neale, J., 2000). 
 
2.10 What aspects of mental health contribute to fatal overdose? 
•    Suicidal ideation (Stewart et al., 2002). 
•    Access to antidepressants. (Oyefeso, A., Valmana, A., Clancy, C., et al., 
2000). 
•    History of mental health problems. (Oyefeso, A., Valmana, A., Clancy, C., et 
al., 2000). 
•    Feelings of indifference and carelessness. (Rossow, I. & Lauritzen, G., 
1999). 
•    Treatment of mental health issues in different services (Oyefeso, A., 
Valmana, A., Clancy, C. et al., 2000). 
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2.11 In what ways do care pathways and service models impact on overdose?  
•    Seeing multiple doctors is a risk factor (e.g. obtaining different drugs from 
different doctors). 
•    Access to prescribed antidepressants (to prevent illicit drug cocktails). 
•    Supervision and monitoring prescriptions (to prevent drug cocktails). 
•    Monitoring and assessing additional substance use ‘on top’ of prescriptions. 
•    Appropriate arrangements for methadone reduction and/or leaving treatment 
because of chaotic use.  
•    Treatment of mental health and physical health in different services.  
•    Conflict with network of users (is it possible to influence drug user’s social 
networks?). 
 
2.12  What special groups were identified, e.g. adolescents, prisoners (in particular 
after prison release), pregnant drug users, and older people?  
•     Homeless drug users (including those with accommodation problems). 
•     Recently released prisoners (especially at two weeks from prison release). 
•     The review did not reveal anything about teenagers, pregnant drug users or 
older people. 
 
2.13 Is it possible to differentiate risk factors (individual, circumstances, and 
responses)  between fatal and non-fatal opiate overdose?  
•     ‘…although there are clearly individual risk factors…and situational risks our 
ability to categorise and predict fatality remains poor’ (Petersen & Best, 
2005).  
•     ‘While significant risk factors for opioid overdose fatality are well recognised, 
the mechanism of fatal overdose remains unclear’ (Warner-Smith et al., 
2001). 
•     While the review did not reveal any new information on this point, the 
decision analysis shows how predictors of fatality can be clarified.  
 
2.14 What are the consequences of a non-fatal overdose (for example, on morbidity)? 
•     No evidence (from this review) that behaviour is modified in such a way as 
to reduce the likelihood of future overdoses. 
•     No evidence (from this review) that it has an impact on morbidity. However, 
several papers have noted that heroin overdose can cause cognitive 
impairment and neurological deficits (e.g. Brvar et al., 2005). 
 
2.15 What are the views of emergency services who attend the scene of an 
overdose? (see Figure 8) 
•     25 % of respondents stated that, generally speaking, overdose incidents 
they are called to occur in potentially dangerous and hostile situations 
(Rome et al., 2008). 
•     Where witnesses intervene, this is regarded by police and ambulance staff 
to be largely helpful (Rome et al., 2008). 
•     Further medical help is often refused by the person who had the overdose 
(Rome et al., 2008). 
•     The majority of police and ambulance staff (75 %) do not provide written 
information to those present at the scene of an overdose (Rome et al., 
2008). 
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•     ‘In every single case, they (i.e. the drug users) are not interested. Family 
members may take a bit of attention’. Scottish Paramedic (Rome et al., 
2008). 
 
 
Figure 8. Why bystanders delay calling an ambulance according the emergency 
service workers 
 
 
Source: (Rome et al., 2008).  
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3 Discussion 
 
The review has highlighted factors that facilitate and impede overdose prevention. Before 
considering these, it is worthwhile highlighting previous recommendations. 
 
Best et al. (2001) assert that ‘most overdoses and deaths are avoidable’. They suggest that 
‘dose is rarely the sole cause — other factors turn the potential for risk into a real danger 
and these factors can be changed by the user and by interventions’. A very important factor 
appears to be using other depressant drugs (alcohol or benzodiazepines) at the same time. 
 
Risk factors that can potentially be targeted by interventions are injecting, suicidal 
tendencies, resuming use after a break (often after imprisonment) and using in situations 
where no one else is available to summon help. The toxicity of available heroin and 
substitutes/supplements which are attractive to addicts can have a major impact on the 
death rate. 
 
Best et al. (2001) recommend methadone maintenance as a treatment that ‘effectively 
reduces the risk of overdose’. Improving uptake and retention is an important way to reduce 
the death rate. However, they acknowledge barriers. Firstly, the addict has to remain in 
treatment. Secondly, without adequate controls, drugs diverted from maintenance 
prescribing can increase deaths among non-patients, but stringent controls could mean 
fewer addicts enter and stay in treatment, increasing their risk of overdose. 
 
Best et al. (2001) recommend that services should be ‘providing information on the risks, 
encouraging users to protect themselves and others, and developing care plans based on 
an assessment of risk’. However, it is not clear to what extent services already do this. 
 
Finally, Best et al. (2001) recommend that, ‘if they witness an overdose, heroin users should 
be encouraged to immediately summon emergency services in the knowledge that only in 
exceptional circumstances would police be called to the scene and/or make an arrest’. 
However, a barrier to this is that ‘reassurance is contingent on local protocols being worked 
out’. 
 
The review by Rome et al. (2008) made several recommendations: 
1. Improve the quality of existing responses to overdose incidents (police and 
ambulance). 
2. Improve the assessment of needs. 
3. Improve and extend current care provision for drug users. 
4. Information and training for emergency service staff. 
5. Information and training for drug users and significant others.  
 
Rome et al. (2008) highlight a ‘cycle of overdose management’. Column 2 of Table 5 
contains an assessment of issues relating to each stage of the cycle. 
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Table 5. Stages in the cycle of overdose management 
Stages in the cycles (Rome et al., 2008) Issues at each stage of the cycle 
Assessment of needs This needs to be holistic; not just focusing on drug 
use. Where and when should assessment be 
made? How should overdose risk be 
conceptualised? 
Harm reduction strategies Various strategies have been suggested and 
implemented. It is unclear which strategies are 
effective (see ‘Table 6. Expert assessment of 
priority of overdose prevention measures’). 
Reduce risk Drug users’ behaviour and knowledge may impede 
efforts to reduce risk 
Recognise overdose ‘Those who have witnessed an overdose can 
recognise the signs and symptoms. What is not 
clear is if they were able to do this before their 
experience of witnessing an overdose incident or 
not’ (Rome et al., 2008). 
Manage overdose situation Witnesses may be willing and able but impeded by 
factors such as diffusion of responsibility, fear of 
police involvement, lack of confidence, own 
intoxication 
Get person to hospital Possible negative attitudes of some health 
professionals has been mentioned in the literature 
Manage medical emergency Lack of protocols or liaison between services 
 
It is relatively straightforward to make recommendations that potentially could prevent 
overdoses. However, it is clear from the above that there are barriers at several levels — 
firstly for drug users, secondly for witnesses, and thirdly for service providers. 
 
Without understanding the dynamics of these groups, the impact of recommendations is 
likely to be limited. For example, is a drug user willing to forgo the pleasure produced by 
injecting drugs to decrease their risk of overdose? If so, for how often? In what 
circumstances? The importance of this is highlighted by the following quote: 
 
‘If the reduction in utility associated with these factors outweighs the 
improvements in utility associated with the health outcome, then from the patient’s 
perspective, the treatment represents a net reduction in well-being.’ (Birch & 
Ismail, 2002). 
 
This statement was made in the context of dental treatment, but has obvious corollaries in 
relation to overdose. Thus, in the final section, we summarise recommendations, potential 
actions and the barriers to their implementation. 
 
In Fife, Scotland Baldacchino and colleagues have developed a questionnaire in order to 
identify trends and patterns within such deaths with the aim of preventing future incidences. 
(see Appendix 2).  
 
Appendix 3 is a case vignette of a typical drug death victim in Fife, Scotland. The vignette 
highlights the issues in implementing measures to prevent fatal overdose. 
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4 Recommendations 
 
This section makes recommendations that could facilitate reduced fatal overdoses but also 
notes barriers. The content of the review was discussed and reviewed at a meeting in 
Dundee, Scotland on 1 April 2010. Attending the meeting were Martin Frisher (Keele 
University), Alex Baldacchino (Consultant Psychiatrist NHS Fife and Clinical Senior Lecturer 
in Addictions, Centre for Addiction Research and Education Scotland (CARES), Dundee 
University), Kenny Cameron (Drugs Strategy Officer, Scottish Crime And Drug Enforcement 
Agency), Dr Julia Neufeind (Drug Deaths Researcher, Fife Alcohol and Drug Partnership 
and Researcher in CAMHS and Public Health, NHS Fife), Mandy Young, Fife ADP, 
Overdose Prevention Coordinator, Fife NHS Addiction Services, NHS Fife, Tahira Akbar 
(Researcher, Centre for Addiction Research and Education Scotland (CARES), Dundee 
University). 
 
The group focused on the extent to which measures might impact among the population of 
opiate users for a while. As mentioned in the introductory note the expert group was ad-hoc 
and geographically specific; other groups might have come to different conclusions. 
 
Table 6 gives an overview of recommendations based on the literature as well as barriers 
mentioned. It also includes the expert group assessment of feasibility and efficacy. 
 
Table 6. Overdose prevention: recommendations, barriers and expert assessment 
Prevention - 
Institutional 
Recommendation • Barriers Expert 
assessment of 
feasibility 
Expert 
assessment 
of efficacy 
Prison 
Coordinated 
release from 
prison 
 
•  Identify and 
implement 
potential 
interventions that 
can reduce drug 
deaths in 
recently-released 
prisoners, e.g. 
links to treatment 
in the community. 
• EMCDDA 
recommends that 
pre-release 
counselling 
should be 
extended 
(EMCDDA, 
2009). 
• If deaths 
following recent 
release from 
prison were 
eliminated, this 
could reduce fatal 
overdose by 
15 %. 
(Department of 
Health, 2007) 
• Patient 
dynamics, e.g. 
desire to take 
drugs outweighs 
other 
considerations. 
• Ignorance of, or 
not caring about, 
reduced 
tolerance. 
• Lack of 
coordination with 
community 
services e.g. 
housing, 
substance 
misuse other 
social services. 
• Day of release 
can be changed 
with little warning 
or take place on 
Friday or 
weekend. 
This depends 
on institutional 
arrangements in 
Member States. 
The expert 
group felt there 
was 
considerable 
regional 
variation. 
Police custody 
cells 
— Arrest referral 
Targeted 
The expert group 
considered this to 
be an important 
point of access for 
at risk individuals.  
At present little is 
done in this setting in 
some places. 
The expert 
group assessed 
this as having 
high feasibility. 
The expert 
group 
assessed this 
as potentially 
having a high 
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prevention of at 
risk individuals 
(Arrested 
individuals known 
to be drug users). 
level of 
efficacy having 
high feasibility. 
Prevention — 
Public Health 
Recommendation Barriers Expert 
assessment of 
feasibility 
Expert 
assessment 
of efficacy 
Pharmacology 
/Toxicology  
Disseminating 
information on 
purity levels, 
composition and 
quantity of drugs 
involved in fatal 
overdoses.  
• Create an 
environment 
where such 
information is 
available. 
• Consolidate 
links with 
toxicologists to 
produce 
detailed and 
accurate reports 
• Vignette: ‘Heath 
Ledger died 
from accidental 
drug overdose, 
medical 
examiner says’ 
http://seattletim
es.nwsource.co
m/html/movies/2
004168938_hea
th07.html 
• Information 
systems are not 
adequate e.g. 
updated on 
changing risks of 
some drugs  
• Data is not 
shared and 
coordinated  
• Data is not 
disseminated to 
drug users and 
health 
professionals 
• Translation of 
analysis of 
information into 
user-friendly 
format 
• Health 
professionals 
have a role in 
making drug 
users aware 
• Will drug users 
change their 
behaviour as a 
result?   
In principle it is 
a good idea to 
make drug 
users and 
health 
professionals 
more aware of 
the overdose 
risks of specific 
drugs and drug 
combinations. 
However, 
current 
information 
tends to be 
generic. Also 
the role of 
specific drugs in 
the death is not 
always clear or 
straightforward. 
Even if such 
information is 
available, its 
utility is unclear. 
It is difficult to 
specify 
efficacy. 
Information is 
often not 
available in a 
manner likely 
to influence 
drug users’ 
behaviour. 
Information 
Better exchange of 
information and 
recording of ‘near 
misses’. 
 
• Closer liaison 
between 
emergency 
services and 
other services 
e.g. substance 
misuse, mental 
health, Accident 
and Emergency 
(A & E), police 
and ambulance 
• Vignette: 
Emergency 
Services Crews 
confronted with 
heroin-fentanyl 
overdoses 
(ODs) 
http://www.jems.co
m/article/medical-
emergencies/clinical
-alert-new-high 
• Collating and 
analysing this 
information. 
• Ensuring 
responders have 
access to the 
information. 
There is 
considerable 
regional 
variation on the 
quality of 
information. 
It is difficult to 
specify 
efficacy. 
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Decision 
support 
Providing drug 
uses and health 
professionals 
with more 
targeted 
information about 
overdose. 
Improve the quality of 
interaction between 
health professionals 
and drug users by 
providing patient-
specific assessment 
of overdose risk. 
• Engaging drug 
users. 
• Engaging health 
professionals 
Pilot scheme to 
evaluate 
decision support 
with health 
professionals 
and drug users 
is necessary by 
different 
methods in 
different 
settings. 
As yet, there 
are no trials of 
decision 
support 
systems. 
Computerised 
decision 
support has 
been shown to 
improve best 
practice 
(Kawamoto et 
al., 2005). 
 
 
 
Prevention — 
Treatment 
Recommendation Barriers Expert 
assessment of 
feasibility 
Expert 
assessment 
of efficacy 
Methadone 
maintenance 
 
 
• Increase 
provision 
• Ensure people do 
not leave 
because of strict 
monitoring 
• Create an 
environment 
where user 
understands the 
needs for 
monitoring due to  
the risks  
• Ensure person is 
in effective 
treatment 
program and is 
not using 
methadone or 
illicit drugs from 
other sources 
• Ensure optimal 
dose of between 
60–120 mg 
• Vignette: 
Management of 
Opioid 
Dependence 
http://www.medsc
ape.com/viewarti
cle/452723 
• Diversion to illicit 
market 
• Combining with 
other drugs 
alcohol, 
benzodiazepines 
and prescription 
drugs (medical 
use or non-
medical use) 
• Many doctors do 
not want to 
prescribe higher 
range doses 
• Difficult to monitor 
in practice 
Experience has 
shown this 
measure is 
feasible (if 
controversial). 
 
Many studies 
have shown 
this measure 
to be 
efficacious. 
However, the 
barriers may 
have 
contributed to 
the problems 
as well (i.e. 
overdose 
caused by 
methadone). 
 
Naloxone • Wider training 
and 
implementation of 
Naloxone 
• Vignettes: 
Overdose rescue 
kits save lives 
http://www.npr.or
g/templates/story/
story.php?storyId
=17578955 
• Not legally 
available 
• User might 
use more 
drugs than 
without 
Naloxone 
More pilot 
schemes are 
required. The 
expert group 
noted that other 
antidote drugs 
could also be 
considered. 
Some studies 
have shown this 
measure to be 
efficacious. 
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• Medical and legal 
issues keep 
overdose 
antidote out of 
users’ hands 
http://www.mapin
c.org/drugnews/v
00.n010.a04.html 
Assessment 
and treatment of 
physical and 
psychiatric/ 
psychological 
health and 
significant life 
events 
 
• Shared 
assessment and 
further integration 
of services 
should encourage 
sharing of 
information and 
treatment plans 
• Targeted 
interventions for 
high-risk patients 
 
• Users not in 
touch with 
services 
• Poor 
coordination 
between 
agencies 
• Willingness to 
engage with 
treatment 
• Attitude of 
health 
professionals 
• Is there 
evidence that 
such 
assessment is 
effective? 
Not directly 
considered, but 
see comments on 
efficacy (next 
column). 
The expert 
group felt that 
this was 
perhaps the 
most important 
factor in 
overdose 
prevention. 
Specialist 
nurses in 
Accident and 
Emergency 
departments 
Ensure such nurses 
are in place 
Is there evidence 
for effectiveness? 
Unclear Difficult to 
quantify. 
Safe injecting 
rooms 
Provide safe injecting 
rooms 
• Resistance 
from 
communities, 
legal 
authorities, 
etc. 
• Do drug users 
want them? 
Depends on 
removal of 
barriers. 
Likely to be 
efficacious. 
 
Prevention — 
individual 
Recommendation Barriers Expert 
assessment of 
feasibility 
Expert 
assessment of 
efficacy 
Provide accurate 
information to drug 
users 
Disseminate 
information on key 
risk and protective 
factors 
• Do drug 
users act on 
such 
information? 
• Drug users 
often engage 
in 
inappropriate 
interventions 
• Previous 
overdose 
does not 
seem to be a 
deterrent 
Important to 
assess under 
what 
circumstances 
drug users would 
change their 
behaviour. 
Could be 
efficacious, 
depending on 
comments in 
feasibility 
column. 
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CPR training Provide CPR 
training 
• Would drug 
users 
participate or 
remember 
CPR 
training? 
• Not only drug 
users, but 
friends and 
family 
Measure is 
feasible. 
The noted 
barrier means 
the efficacy of 
this measure is 
unclear. 
Use of 
antidepressant 
drugs 
• Ensure 
antidepressant 
drugs are not 
over-
prescribed 
• Safety 
measures 
required, e.g. 
coordination of 
mental health 
and substance 
misuse 
Use of 
antidepressant 
drugs is part of 
their substance 
misuse but also 
part of treatment 
of comorbidity. 
• Difficult to 
implement 
• In what way? 
Could be 
dispensed 
frequently 
and 
monitored? 
Patient 
regularly 
reviewed for 
mental health 
Likely to be 
efficacious if 
implemented. 
Using the 
consultative and 
integrated 
models rather 
than serial or 
parallel models 
in comorbid 
conditions. 
 
 
Overdose 
response — 
Setting 
Recommendation Barriers Expert 
assessment of 
feasibility 
Expert 
assessment of 
efficacy 
Bystanders 
If individuals have 
others close to 
them at the time of 
overdose, this 
provides the 
opportunity for 
overdose training 
for these 
individuals.   
• Education, 
integration and 
delivery of 
effective 
interventions 
• Family 
members of 
drug users 
should be 
provided with 
overdose 
training so they 
can recognise 
signs of 
overdose, such 
as snoring  
• Family 
members, 
peers, general 
population 
ought to be 
provided with 
CPR training, 
which would 
allow them to 
intervene and, 
perhaps, 
prevent the 
death 
 
• Substance 
misusers do 
not want 
training 
• Bystanders 
are 
themselves 
intoxicated 
• Witnesses 
leave the 
scene of the 
overdose 
• Diffusion of 
responsibility 
• Drug users 
who survive an 
overdose and 
go on to 
witness others 
having an 
overdose are 
less likely to 
intervene 
(Tobin) 
• Possible 
repercussions, 
e.g. children 
are in the 
house 
Difficult to 
translate into 
action due to 
barriers. 
Depends on 
removal of the 
barriers. 
Police 
 
Ensure police do not 
attend overdose 
unless a death has 
occurred 
Overdose 
incidents can 
occur in potentially 
dangerous and 
hostile 
This already 
happens in some 
place but there 
are other issues, 
e.g. child 
Unclear 
31 
environments, 
where police may 
have to attend. 
protection. 
Ambulance Trained in Naloxone 
use. 
Vignette: 
http://www.jems.co
m/news_and_article
s/articles/jems/3201/
clinical_alert_the_ne
w_high.html  
May not be routine 
in some areas. 
 
Should be 
feasible in most 
settings. 
Efficacious in 
dealing with 
near misses. 
Direct referrals 
from ambulance 
to treatment 
services as an 
option of 
improving 
therapeutic 
opportunities for 
those who have 
recently 
overdosed. 
 
After considering the information in Table 6, the expert groups discussed the measures. The 
key point is the group viewed overdose prevention as a multifaceted problem. Purely 
technological interventions were though likely to have a relative limited impact. Rather, 
overdose involves personal and societal issues; only when these are addressed is the level 
of fatal overdose likely to decrease. 
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6 Appendix 1: Analysis of overdose papers 
 
Each paper mentioned was summarised with respect to: 
 
1. Intervention or activity related to overdose 
2. Did the intervention/activity increase or decrease the likelihood of fatal overdose? 
3. Study population 
4. Defined outcome, e.g. non-fatal or fatal overdose 
5. Issues arising 
6. Country where the study was conducted 
7. Reference 
 
The papers are categorised as follows. 
 
1. Risk factors (individual and social) 
a. Patterns of drug use 
b. Other health factors 
c. Suicide risk 
d. Psychosocial factors 
2. Treatment interventions to prevent overdose 
a. Methadone 
b. Naloxone 
c. Other prescriptions 
d. Safe injecting rooms 
e. Engagement with services 
3. Organisational responses 
a. Emergency responses 
4. Responses following overdose 
a. Other drug users/overdose witnesses 
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 Intervention or 
activity related 
to overdose 
Increase or 
decrease 
likelihood of 
fatal 
overdose 
Study 
population 
Defined 
outcome 
Issues arising Country Reference 
1 Risk factors (individual and social) 
1.a Patterns of drug 
use 
      
1.a Reduction in rate 
of injecting 
behaviour. 
 
 Decrease Drug 
injectors? 
Overdose 
 
 Scotland Neale & 
Robertson, 
2005. op. cit. 
 
1.a Alcohol and 
opiate-based 
drugs in 
combination with 
SSRI anti-
depressants. 
 
 Increase Not stated Fatal anti-
depressant 
overdose 
(FAO). 
 
93 % of deaths 
from SSRIs 
occurred in 
combination with 
other drugs, 
especially TCAs 
(24.5 %). 
UK Cheeta, S., 
Schifano, F., 
Oyefeso, A., et 
al. (2004). 
Antidepressant-
related deaths 
and 
antidepressant 
prescriptions in 
England and 
Wales, 1998–
2000, British 
Journal of 
Psychiatry, 184, 
pp. 41–47. 
 
1.a Very high levels 
of drug intake, 
with users 
experiencing 
difficulty in 
controlling their 
drug intake. 
 Increase Not stated Non-fatal 
overdose 
 
 Dorset Bennett et al., 
1999 
 
1.a High levels of 
polydrug use and 
prescription drug 
use;  
increasing use of 
multiple doctors; 
excessive 
increases in 
psychoactive drug 
prescriptions. 
 Increase Not stated Died of 
heroin-
related 
overdose. 
 
 Australia Martyres, R.F., 
Clode, D. & 
Burns, J.M. 
(2004), ‘Seeking 
drugs or seeking 
help? Escalating 
“doctor 
shopping” by 
young heroin 
users before 
fatal overdose’, 
Medical Journal 
of Australia, 
180, pp. 211–
214. 
 
1.a Period of 
abstinence from 
regular use. 
 
 Increase Accidental 
fatalities 
 
Suggests that 
decreased 
tolerance is a 
key factor in 
fatal 
overdose. 
Suggested 
that one in 
five deaths 
were after a 
period of 
abstinence 
from regular 
use.  
Reduced tolerance 
to opioids.  
Frequently reported 
reasons for 
abstinence were 
imprisonment and 
hospital admission.   
Sheffield 
 
Oliver, P. & 
Keen, J. (2003), 
‘Concomitant 
drugs of misuse 
and drug using 
behaviours 
associated with 
fatal opiate 
related 
poisonings in 
Sheffield, UK, 
1997-2000’, 
Addiction, 98,  
pp. 191–197. 
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1.a Two weeks after 
release, from 
prison compared 
to at other times 
of liberty. 
 
Increase 
Drug-
related 
mortality 
 
Drug-related mortality 
seven times higher in 
first two weeks of 
liberty than at other 
times.  
 UK Bird, S. & 
Hutchinson, S. 
(2003), ‘Male 
drugs-related 
deaths in the 
fortnight after 
release from 
prison: 
Scotland, 
1996–99’, 
Addiction, 98, 
pp. 185–190. 
 
1.a Sporadic use of 
heroin 
 
 
 
Increase 
Not stated Not stated Particular 
significance in 
cases of 
heroin-related 
deaths 
involving 
administration 
routes other 
than injection. 
 
Stock-
holm 
 
Thiblin, I., 
Eksborg, S., 
Petersson, A., 
et al. (2004), 
‘Fatal 
intoxication as 
a consequence 
of intranasal 
administration 
(snorting) or 
pulmonary 
inhalation 
(smoking) of 
heroin’, 
Forensic 
Science 
International, 
139, pp. 241–
247. 
 
1.a Periods of 
induction and 
transition, such as 
when drug users 
(re)enter or 
discontinue 
treatment. 
 
 
Increase 
Not stated Not stated  Australia Bell and Zador, 
2000. 
 
1.a Benzodiazepine 
use 
 
 
Increase 
Drug 
injectors? 
Overdose 
 
 England Stewart et al., 
2002. op. cit. 
 
1.a Benzodiazepine 
use 
 
 
Increase 
 28-fold increase in risk 
of overdose with 
benzodiazepine use.  
 Australia Dietze, P., 
Jolley, D., Fry, 
C., et al. 
(2005), 
‘Transient 
changes in 
behaviour lead 
to heroin 
overdose: 
Results from a 
case-crossover 
study of non-
fatal overdose’, 
Addiction, 100,  
pp. 636–642. 
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1.a Benzodiazepine 
use 
 
  Increase 
or decrease 
depending of 
circumstances 
Drug 
injectors? 
Overdose 
 
 Scotland Neale, J. & Robertson, 
M. (2005) Recent life 
problems and non-
fatal overdose among 
heroin users entering 
treatment. Addiction, 
100, pp. 168–175. 
 
1.a Large quantities 
of alcohol 
 
 Increase  Not stated Not stated  England Stewart et al., 2002. 
op.cit. 
 
1.a Large quantities 
of alcohol  
 Increase Not stated Those 
drinking 
large 
amounts of 
alcohol 
were at 
greater risk 
of 
overdose.  
 Various  Gossop et al., 2002, 
McGregor, C., Darke, 
S., Ali, R., et al. 
(1998), ‘Experience of 
non-fatal overdose 
among heroin users in 
Adelaide, Australia: 
Circumstances and 
risk perceptions’, 
Addiction, 93, pp. 
701–711. 
1.a Injecting cocaine 
users 
 
 Increase Not stated Cocaine 
overdose 
was more 
common 
among 
injecting 
cocaine 
users.  
 
 USA Bernstein, K.T., 
Bucciarelli, A., Piper, 
T.M. et al. (2007), 
‘Cocaine- and opiate-
related fatal overdose 
in New York City, 
1990–2000’, BMC 
Public Health, 7, p. 31. 
 
1.a Injecting drug use 
in public places 
 
 Increase Not stated Injecting in 
public 
places 
strongly 
associated 
with 
overdose. 
 Scotland Taylor, A., Cusick, L., 
Kimber, J. et al. 
(2006), The Social 
Impact of Public 
Injecting (Paper D). 
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1.a Changes in police 
activity whereby 
dealing and use 
at static sites, 
such as houses, 
is displaced to 
street dealing in 
other areas. 
 Increase Not stated Not stated  Australia Fitzgerald, J., 
Hamilton, M. & 
Dietze, P. (2000), 
‘Walking overdoses: 
A re-appraisal of 
non-fatal illicit drug 
overdose’, Addiction 
Research, 8,  
pp. 327–355. 
1.a Public injecting 
 
 Decrease Not stated Not stated Public intervened to help 
overdosed or 
unconscious drug users. 
Some did this as part of 
their job, and others did it 
voluntarily. 
Scotland Taylor et al., 2006. 
op. cit. 
 
1.b Other health 
factors 
      
1.b High levels of 
hepatitis and 
cirrhosis 
 
 Increase Not stated Not stated May increase the risk of 
hypoxia-induced cardiac 
arrest and 
arrhythmia. 
 
Australia Darke, S., Kaye, S. & 
Duflou, J. (2006), 
‘Systemic disease 
among cases of fatal 
opioid toxicity’, 
Addiction, 101,  
pp. 1299–1305. 
 
1.b Progressive 
disease burden 
 
 Increase Not stated Not stated  Australia Darke et al., 2006. 
op.cit 
 
1.c Suicide risk       
1.c Opiate users  
 
 
N/A Not stated Fatal 
overdose 
 
Difficulties in 
distinguishing between 
accidental and intentional 
overdose. 
  
England Farrell, M., 
Neeleman, J., 
Griffiths, P., et al. 
(1996), ‘Suicide and 
overdose among 
opiate addicts’, 
Addiction, 91,  
pp. 321–323. 
 
1.c Methadone 
 
 Increase Not stated Overdose 
suicide 
 
 UK Oyefeso, A., 
Ghodse, H., Clancy, 
C., et al. (1999), 
‘Suicide among drug 
addicts in the UK’, 
British Journal of 
Psychiatry, 175, pp. 
277–282. 
 
1.c Distressing life 
event 
 
 Increase Not stated Not stated Intentional overdoses 
 
UK Neale, 2000. 
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1.c Suicidal ideation 
 
 
Increase 
Not stated Non-fatal 
overdose 
 
 England Stewart et al., 2002.  
op. cit. 
 
1.c History of mental 
health problems, 
a current 
psychiatric 
diagnosis and 
having been 
prescribed 
psychotropic 
medicines 
 
Increase 
Not stated Fatal non-
deliberate 
overdose 
 
 UK Oliver, P., Horspool, M., 
Rowse, G., et al. 
(2007), A Psychological 
Autopsy Study of Non-
Deliberate Fatal Opiate-
Related Overdose, 
London: National 
Treatment Agency for 
Substance Misuse. 
1.c Problem drug 
users expressing 
suicidal ideation 
 
 
Increase 
Not stated Not stated  Scotland Jones, R., Gruer, L., 
Gilchrist, G., et al. 
(2002), ‘Recent contact 
with health and social 
services by drug 
misusers in Glasgow 
who died of a fatal 
overdose in 1999’, 
Addiction, 97,  
pp. 1517–1522. 
 
1.c Feelings of 
indifference and 
carelessness 
 
 
Increase 
Not stated Not stated Overdose 
survivors 
 
 Rossow, I. & Lauritzen, 
G. (1999), ‘Balancing on 
the edge of death: 
Suicide attempts and 
life-threatening 
overdoses among drug 
addicts’, Addiction, 94, 
pp. 209–219. 
1.d Psychosocial 
factors 
      
1.d Increasing age 
 
 
Increase 
Not stated Number of 
overdose 
episodes 
 
 Australia Warner-Smith, M., 
Darke, S., Lynskey, M., 
et al. (2001), ‘Heroin 
overdose: Causes and 
consequences’, 
Addiction, 96, pp. 1113–
1125. 
 
1.d Length of time 
that people have 
used 
 
 
Increase 
Not stated Not stated Length of time 
may be 
stronger 
indicator than 
chronological 
age.  
Australia Bartu et al., 2004. op. 
cit 
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1.d More self-
reported 
psychological 
health problems 
at treatment 
intake and at one 
year follow-up. 
 
 
Increase 
Not 
stated 
Non-fatal 
overdose 
 
 England Stewart et al., 
2002. op. cit. 
 
1.d More drug 
injectors in the 
social network; 
experiencing 
conflict with more 
network members 
 
 
 
Increase 
Not 
stated 
Not 
stated 
Number of drug injectors in a 
person’s social network and 
number of networks they are in 
conflict with.  
USA Latkin, C.A., 
Hua, W. & 
Tobin, K. (2004), 
‘Social network 
correlates of 
self-reported 
non-fatal 
overdose’, Drug 
and Alcohol 
Dependence, 
73, pp. 61–67. 
 
1.d Accommodation 
problems 
 
 
Increase 
Not 
stated 
Not 
stated 
Obtaining a tenancy could 
increase the potential for fatal 
overdose due to solitary drug 
use. 
England Neale & 
Robertson, 
2005. op. cit. 
 
1.d Hostel 
accommodation 
 
 
Increase 
Not 
stated 
Not 
stated 
Paradoxically, although the 
hostel setting could contribute to 
one risk factor (increased heroin 
consumption), the practice of 
using in a group could also 
protect against fatal overdoses 
due to the presence of a third 
party who could attempt 
resuscitation and / or alert 
emergency services. 
England Wright, N., 
Oldaham, N. & 
Jones, L. 
(2005), 
‘Exploring the 
relationship 
between 
homelessness 
and risk factors 
for heroin-
related death: A 
qualitative 
study’, Drug and 
Alcohol Review, 
24, pp. 245–
251. 
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2 Treatment to prevent overdose 
2.a 2a. Methadone       
2.a Methadone 
diversion 
 
 Increase 33 drug 
overdose 
casualties 
attending six 
accident and 
emergency 
departments in 
two Scottish 
cities 
Non-fatal 
overdose 
 
Tighter 
supervision 
of methadone 
consumption 
in 
pharmacies 
and drug 
clinics. 
Scotland Neale, 2000. op. 
cit. 
2.a Casualties that 
consumed 
methadone prior 
to overdose cited 
a range of 
explanations — 
from 
unintentionally 
taking too many 
drugs and 
unexpected 
heroin purity to a 
lower tolerance or 
ingesting 
unknown tablets. 
 Increase 33 drug 
overdose 
casualties 
attending six 
accident and 
emergency 
departments in 
two Scottish 
cities 
Non-fatal 
overdose 
 
 Scotland Neale, 2000. op. 
cit. 
2.a Greater benefit 
being accrued 
from offering most 
individuals on 
methadone 
maintenance a 
daily dose 
between 60 mg 
and 120 mg. 
 
 Decrease Not stated Higher doses 
shown to 
encourage 
treatment 
retention and 
reduce illicit 
drug use in 
methadone 
maintenance 
regimens. 
 England National 
Treatment 
Agency for 
Substance 
Misuse (2004). 
op. cit. 
 
2.a Strict rules (for 
methadone 
programmes) 
increasing the risk 
of discharge, 
resulting in a high 
mortality rate. 
 
 Increase Opiate users 
who had been 
in contact with a 
methadone 
treatment 
programme 
Fatal heroin 
overdose 
 
 Sweden Fugelstad et al. 
(2007).  op.cit. 
 
2.a Methadone —
where tolerance is 
reduced 
 
 Increase Methadone-
related mortality 
 
Not stated  UK Wolff and 
colleagues 
(2002) 
 
2.a Methadone dose 
is increased too 
quickly, or the 
initial dose is too 
high. 
 Increase Methadone-
related mortality 
Not stated Problems 
may arise if 
the person’s 
methadone 
dose is 
increased too 
quickly, or if 
the initial 
dose is too 
high. 
UK Wolff, K. (2002) 
Characterisation 
of methadone 
overdose: 
Clinical 
considerations 
and the scientific 
evidence. 
Therapeutic 
Drug Monitoring, 
24, pp. 457–
470. 
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2a Overdose 
situations related 
to methadone and 
methadone 
treatment: 
• Topping up on 
a legitimate 
methadone 
prescription. 
• Using 
someone 
else’s 
methadone 
prescription. 
• Preferring 
illegal drug use 
to prescribed 
methadone. 
• Unable to 
access a 
methadone 
prescription. 
 Increase 33 drug 
overdose 
casualties 
attending six 
accident and 
emergency 
departments in 
two Scottish 
cities 
Non-fatal 
overdose 
 
 Scotland Neale, J. (2000), 
‘Suicidal intent 
in non-fatal illicit 
drug overdose’, 
Addiction, 95, 
pp. 85–93. 
2a Unable to obtain 
substitute 
medication 
 
 Increase 33 drug 
overdose 
casualties 
attending six 
accident and 
emergency 
departments in 
two Scottish 
cities 
Non-fatal 
overdose 
 
Substitute 
prescribing 
should 
include 
opinions and 
concerns of 
drug users. 
Scotland Neale, 2000.  
op. cit. 
2a 2a. More frequent 
users of illicit 
methadone  
 
 Increase Clients in 
treatment 
Overdosed in 
the three 
months prior to 
treatment 
 
Cullen notes 
that most 
people 
involved in a 
structured 
methadone 
programme 
reported 
continued 
illicit drug 
use.  
England Stewart, D., 
Gossop, M. & 
Marsden, J. 
(2002), 
‘Reductions in 
non-fatal 
overdose after 
drug misuse 
treatment: 
Results from the 
National 
Treatment 
Outcome 
Research Study 
(NTORS)’, 
Journal of 
Substance 
Abuse 
Treatment, 22, 
pp. 1–9. 
 
2.b Naloxone       
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2.b 2b. Take-home-
Naloxone (THN) 
 
 Decrease Not stated Overdose 
fatalities  
 
Two thirds of 
the 69 
overdose 
fatalities could 
have been 
prevented with 
immediate 
administration 
of THN. Most 
drug overdose 
deaths occur in 
the company 
of others. 
England Strang, J., 
Powis, B., 
Best, D., et al. 
(1999), 
‘Preventing 
opiate 
overdose 
fatalities with 
Take-home 
Naloxone: Pre-
launch study of 
possible 
impact and 
acceptability’, 
Addiction, 94, 
pp. 199–204. 
 
2.b 2b. Take-home-
Naloxone (THN) 
 
 Decrease 18 overdoses 
were witnessed 
and 10 
Naloxone 
administrations 
 
Success in 
overdose 
reversal 
 
Biggest 
challenge was 
to raise 
awareness and 
provide 
training. 
England Strang, J., 
Manning, V., 
Mayet, S., et 
al. (2007), The 
Naloxone 
Programme: 
Investigation of 
the wider use 
of naloxone in 
the prevention 
of overdose 
deaths in pre-
hospital care, 
London: 
National 
Treatment 
Agency for 
Substance 
Misuse. 
 
 
2.b 2b. Take-home-
Naloxone (THN): 
Drug users were 
unlikely to engage 
in riskier drug-
taking activity 
 
 Decrease Not stated Not stated  USA Worthington, 
N., Piper, T.M., 
Galea, S., et 
al. (2006), 
‘Opiate users’ 
knowledge 
about 
overdose 
prevention and 
Naloxone in 
New York City: 
A focus group 
study’, Harm 
Reduction 
Journal, 3. 
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2.b Take-home-
Naloxone (THN) 
 
 Increase Not stated Not stated 46 % stated 
that they might 
not be able to 
dissuade the 
casualty from 
using more 
heroin 
following 
THN 
administration 
 
 Seal, K.H., 
Downing, M., 
Kral, A.H., et 
al. (2003), 
‘Attitudes 
about 
prescribing 
Take-home 
Naloxone to 
injection drug 
users for the 
management 
of heroin 
overdose: A 
survey of 
street-recruited 
injectors in the 
San Francisco 
Bay area’, 
Journal of 
Urban Health, 
91,  pp. 1842–
1846. 
2.b Intranasal 
Naloxone 
 
 Decrease Not stated Safe and 
effective option  
 USA Kerr, D., 
Dietze, P. & 
Kelly, A.M. 
(2008), 
‘Intranasal 
Naloxone for 
the treatment 
of suspected 
heroin 
overdose’, 
Addiction, 103,  
pp. 379–386. 
 
2.c Other prescription 
medications 
      
2.c Not always taking 
prescribed 
medication, which 
may have 
prompted reduced 
drug tolerance, 
withdrawals and 
an increased 
susceptibility to 
overdose. 
 
 Increase 33 drug 
overdose 
casualties 
attending six 
accident and 
emergency 
departments in 
two Scottish 
cities 
Non-fatal 
overdose 
 
 Scotland Neale, 2000. 
op. cit. 
2.c Access to anti-
depressants 
through genuine 
prescriptions; 
obtaining different 
antidepressants 
from different 
prescribers. 
 
 
 Increase Not stated Fatal anti-
depressant 
overdose 
(FAO). 
 
Carefully 
evaluate drug 
abuse history 
of women with 
an affective 
disorder to 
reduce the risk 
of 
antidepressant 
misuse. 
 
England Oyefeso, A., 
Valmana, A., 
Clancy, C., et 
al. (2000), 
‘Fatal 
antidepressant 
overdose 
among drug 
abusers and 
non-drug 
abusers’, 
American 
Journal of 
Preventive 
Medicine, 31, 
pp. 261–264. 
2.d Safer injecting 
rooms 
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2.d Advocates of 
safer injecting 
rooms (SIRs) 
claim that these 
facilities can help 
reduce harms 
associated with 
intravenous drug 
use, such as 
heroin overdose 
levels (fatal and 
non-fatal)  
 
 
 Decrease Not stated Not stated Depends on 
variables, 
such as the 
extent to 
which they 
reach their 
target 
population 
and the 
number of 
deaths 
occurring 
outside that 
target 
population — 
for example, 
those who 
use in private 
and those 
who use 
among more 
socially 
integrated 
users. 
 Hunt, N. 
(2006), The 
evaluation 
literature on 
drug 
consumption 
rooms (Paper 
B). 
 
2.d Safer injecting 
rooms (SIRs) 
 
 Decrease  Staff assisted 
in 377 cases, 
52 % involving 
respiratory 
arrest. No 
overdose 
deaths.  
Decreased 
risk of fatal 
overdose  
Barcelona, 
Spain 
 
Anoro, M., 
Lundain, E. & 
Santisteban, 
O. (2003), 
‘Barcelona’s 
safer 
injection 
facility — 
Eva: A harm 
reduction 
program 
lacking 
official 
support’, 
Journal of 
Drug Issues, 
33,  
pp. 689–712. 
 
2e Engagement with services 
2.e Retention for 
long-term and 
maintenance 
clients as a 
means of 
preventing 
overdose and 
importance of 
adequate follow-
up.  
 Decrease Not stated Risk of 
overdose in 
first 30 days 
after stopping/ 
completing 
treatment was 
three times 
higher, 
compared to 
31 days or 
more.  
The importance 
of adequate 
follow-up among 
abstinence-
based 
treatment 
providers and 
educating drug 
users about the 
risks of post-
treatment 
relapse 
and overdose  
Italy Davoli, M., 
Bargagli, A.M., 
Perucci, C.A., et 
al. (2007), ‘Risk 
of fatal overdose 
during and after 
specialist drug 
treatment: The 
VEdeTTE study, 
a national multi-
site prospective 
cohort study’, 
Addiction, 102,  
pp. 1954–1959. 
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2.e Range of 
measures from 
encouraging 
peers to seek 
medical help to 
providing them 
with controlled 
amounts of 
methadone or 
buprenorphine to 
ensure the 
casualty 
experiences some 
relief from drug 
withdrawal. 
 
 
 
Increase 
or 
decrease 
depending 
on 
circumstan
ces 
Not stated Witnesse
s only 
called an 
ambulan
ce in 
about 
one in 10 
overdose 
incidents
. No 
reported 
interventi
on took 
place in 
nearly 
eight out 
of 10 
deaths.  
Piper and colleagues 
(2007) conclude that 
programme 
experiences and data 
show that these 
initiatives are a 
feasible option in 
training drug users to 
respond effectively to 
overdose by 
administering THN. 
Need for flexibility and 
simplicity in 
development and 
implementation.  
 Lenton, S. & 
Hargreaves, K. 
(2000), ‘A trial of 
Naloxone for peer 
administration has 
merit, but will the 
lawyers let it 
happen?’ Drug and 
Alcohol Review, 19,  
pp. 365–369. 
 
2.e Previous hospital 
contact (within 
five years of 
death). 
 
Decrease 
Drug-
related 
deaths 
Not 
stated 
Other European 
studies have also 
identified missed 
opportunities for 
intervening in medical 
settings Pollini et al, 
2006; Cook, S., 
Moeschler, O., 
Michaud, K., et al. 
(1998), Addiction, 93, 
pp. 1559–1565. The 
studies noted that the 
number of patients 
receiving treatment 
information from 
emergency 
departments or 
hospital staff was low, 
as were the numbers 
referred on to drug 
treatment. 
UK Thanacoody, R., 
Jay, J. & Sherval, J. 
(2007), ‘The 
association between 
drug-related deaths 
and prior contact 
with hospital-based 
services’.   
 
Unpublished at the 
time of the review. 
 
2.e Periods of 
hospitalisation 
providing a 
‘unique’ 
opportunity for 
appropriate 
interventions to 
be targeted at 
these high-risk 
patients. 
 
 
Decrease 
Not stated Methado
ne-
related 
deaths 
60% had attended 
accident and 
emergency 
departments for 
deliberate self-harm or 
accidental overdose. 
UK Fiddler, C., Squires, 
T., Sherval, J., et al. 
(2001),  ‘A review of 
GP records relating 
to methadone-
associated deaths in 
the Lothian region of 
Scotland 1997–9’, 
Journal of 
Substance Use, 6,  
pp. 96–100. 
 
2.e Substance use 
specialist nurses 
within the 
accident and 
emergency 
department to 
progress referral 
for drug overdose 
casualties. 
 
 
Decrease 
Accident 
and 
emergency 
department 
 
Not 
stated 
 Scotland Rome, A., Shaw, A. 
& Boyle, K. (2008), 
Reducing drug 
users’ risk of 
overdose, 
Edinburgh, Scottish 
Government Social 
Research. 
2.e Poor treatment 
response 
 
 
Increase 
Not stated Non-fatal 
overdose 
 
Many treatment 
episodes for drug 
users are suddenly or 
prematurely terminated 
with no opportunity for 
transition.    
Canada Fischer, B., 
Brissette, S., 
Brochu, S., et al. 
(2004), 
‘Determinants of 
overdose incidents 
50 
among illicit opioid 
users in 5 Canadian 
cities’, Canadian 
Medical Association 
Journal, 171, pp. 
235–239. 
 
 
 
2.e Leaving treatment 
 
 
Increase  
Not 
stated 
Overdose  Australia Bartu, A., Freeman, 
N.C., Gawthorne, G.S., 
et al. (2004), ‘Mortality 
in a cohort of opiate 
and amphetamine 
users in Perth, Western 
Australia’, Addiction, 
99,  
pp. 53–60; 
Digiusto, E., 
Shakeshaft, A., Ritter, 
A., et al. (2004), 
‘Serious adverse 
events in the Australian 
National Evaluation of 
Pharmacotherapies for 
Opioid Dependence 
(NEPOD)’, Addiction, 
99,  
pp. 450–460. 
 
2.e Engaged in 
treatment  
 
 
Decrease 
Not 
stated 
Risk of 
death  
Overdose declined 
by half following 
enrolment in 
treatment. Risk 
further reduced the 
longer they stayed in 
treatment (Darke et 
al., 2005) 
Perth, 
Australia 
(Bartu 
op. cit.) 
 
Darke, S., Williamson, 
A., Ross, J., et al. 
(2005), ‘Non-fatal 
heroin overdose, 
treatment exposure and 
client characteristics: 
Findings from the 
Australian Treatment 
Outcome Study 
(ATOS)’, Drug and 
Alcohol Review, 24, pp. 
425–432; Fugelstad, 
A., Stenbacka, M., 
Leifman, A., et al. 
(2007), ‘Methadone 
maintenance treatment: 
The balance between 
life-saving treatment 
and fatal poisonings’, 
Addiction, 102,   
pp. 406–412. 
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2.e Greater number 
of separate 
treatment 
episodes.  
 
 Increase Not stated Greater 
number of 
overdoses  
Importance of 
treatment 
stability, 
longer spells 
in services 
and less 
treatment 
episodes to 
improve 
outcomes. 
Australia Darke et al. 
(2006). op. cit. 
 
2.e Withdrawal from 
drug treatment 
 
 Increase  Unintentional 
illicit drug 
overdose 
Most deaths 
occurred 
among those 
out of 
treatment for 
more than 
two weeks. 
Italy Preti, A., Miotto, 
P. & de Coppi, 
M. (2002), 
‘Deaths by 
unintentional 
illicit drug 
overdose in 
Italy, 1984–
2000’, Drug and 
Alcohol 
Dependence, 
66,  
pp. 275–282. 
 
2.e Increasing the 
availability of 
treatment among 
heroin users both 
in the community 
and in prison 
Decrease Not stated Drug-related 
deaths 
 England Hickman, M., 
Carrivick, S., 
Paterson, S., et 
al. (2007), 
‘London audit of 
drug-related 
overdose 
deaths: 
Characteristics 
and typology 
and implications 
for prevention 
and monitoring’, 
Addiction, 102,  
pp. 317–323. 
 
2.e Unfavourably 
discharged from 
drug treatment 
programme.  
 
 
 Increase 397 in treatment 
(followed 110 
following 
discharge)  
4/397 died while 
in treatment; 
9/110 died 
following 
discharge.  
Death rates, 
especially 
overdose, are 
high among 
patients who 
are 
unfavourably 
removed or 
withdraw from 
treatment 
programmes. 
Six out of 110 
died of heroin 
overdose in 
the 12 months 
following 
withdrawal 
Discharged 
patients were 
eight times 
more likely to 
be dead 
compared to 
those still in 
treatment 
Sweden  Zanis, D.A. & 
Woody, G.E. 
(1998), ‘One-
year mortality 
rates following 
methadone 
treatment 
discharge’, Drug 
and Alcohol 
Dependence, 
52, pp. 257–
260. 
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3 Emergency organisational responses following overdose  
3. Emergency 
responses 
      
3.a Immediate 
overdose onset  
Decrease Not stated Non-fatality Because 
rapid 
overdoses 
are more 
likely to result 
in witnesses 
intervening 
UK Best et al., 
2001. op. cit. 
3.a Slow overdose 
onset. 
Increase Not stated Fatality Because 
slow 
overdoses 
are less likely 
to result in 
witnesses 
intervening. 
UK Best et al., 
2001. op. cit. 
3.a Mapping high-risk 
areas and 
identifying those 
repeatedly 
overdosing. It also 
led to the 
identification of 
high-risk groups 
(in this case, 
young people) not 
previously 
identified by 
services with 
subsequent help 
being offered, 
which included 
drug counselling. 
 
Decrease Not stated Emergencies 
where a 
diagnosis of 
heroin or 
opiate 
overdose was 
recorded. 
More than 
half (52 %) of 
all the 1 087 
emergencies 
were 
attributed to 
189 drug 
users. 
Austria Seidler, D., 
Schmeiser-
Rieder, A., 
Schlarp, O., et 
al. (2000), 
‘Heroin and 
opiate 
emergencies in 
Vienna: Analysis 
at the municipal 
ambulance 
service’, Journal 
of Clinical 
Epidemiology, 
53,  
pp. 734–741. 
 
3.a Establishing a 
database of non-
fatal heroin 
overdoses 
attended to by 
ambulance 
personnel. 
 
Decrease Not stated Database of 
non-fatal 
heroin 
overdoses 
Low police 
attendance at 
drug 
overdose 
scenes 
(12 %). 
Strong links 
between 
researchers 
and the 
ambulance 
service may 
serve as the 
basis for 
important 
future 
research 
regarding 
heroin 
overdose. 
Australia Dietze et al., 
2000. op. cit. 
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3.a ‘Fear’ of police 
involvement is a 
barrier to calling 
for help. 
 
 
Increase 
Not stated Not stated Despite this 
fear, Dietze et 
al. (2000) noted 
low police 
attendance 
(12 %) at drug 
overdose 
scenes. 
Various 
 
Bennett, G.A. & 
Higgins, D.S. (1999), 
‘Accidental overdose 
among injecting drug 
users in Dorset, UK’, 
Addiction, 94,  
pp. 1179–1190; Pollini 
et al., 2006; Tobin et 
al., 2005; Tracey et 
al., 2005 
 
3.a Reducing police 
attendance at the 
scene of an 
overdose and 
decreasing the 
risk of arrest 
might increase 
willingness to call 
emergency 
services. 
 
Decrease 
Not stated Not stated This barrier 
requires 
research to 
provide a better 
understanding of 
drug users’ fear 
of arrest and 
how barriers can 
be reduced. 
Has been 
tried by 
some police 
forces in the 
UK but not 
formally 
evaluated 
Pollini et al., 2006. op. 
cit. 
4 Responses following overdoses. Individual responses:  Other drug users/overdose witnesses 
4 Witnesses 
present at an 
overdose event 
are willing to 
intervene, for 
example, with 
Cardiopulmonary 
Resuscitation 
(CPR). 
Decreas
e 
Not stated Not stated Evidence of the 
opportunity and 
willingness of 
witnesses to 
intervene 
although these 
may often be 
inappropriate 
and wrongly 
prioritised. 
UK Best, D, Gossop, M, 
Man, L.H.,et al. 
(2002), ‘Peer 
overdose 
resuscitation: Multiple 
intervention strategies 
and time to response 
by drug users who 
witness overdose’, 
Drug and Alcohol 
Review, 21,  pp. 269–
274. 
4 Past witnesses of 
a fatal overdose.  
 
Decreas
e 
Not stated Almost 
twice as 
likely to call 
emergency 
services 
Witnessing a 
fatality may 
‘sensitise drug 
users to the 
seriousness of 
overdose’ 
Not stated Tobin, K.A., Davey, 
M.A. & Latkin, C.A. 
(2005), ‘Calling 
emergency medical 
services during drug 
overdose: An 
examination of 
individual, social and 
setting correlates’, 
Addiction, 100, pp. 
397–404. 
 
4 Drug users who 
have survived an 
overdose and go 
on to witness an 
overdose. 
Increase Not stated They feel 
more 
competent 
in managing 
the situation 
themselves. 
Less aware of 
the life-
threatening 
nature of the 
situation and 
less likely to call 
an ambulance 
Not stated  Tobin et al., 2005. op. 
cit. 
 
4 Witnesses of 
overdose events 
in public areas.  
 
Decreas
e 
Not stated More likely 
to summon 
medical 
help 
compared 
to when 
overdose 
occurred in 
a private 
location. 
 US Tracey, M., Piper, 
T.M., Ompad, D., et 
al. (2005), 
‘Circumstances of 
witnessed drug 
overdose in New York 
City: Implications for 
intervention’, Drug 
and Alcohol 
Dependence, 79,  
pp. 181–190. 
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4 Presence of 
bystanders.  
 
Increase Not stated Having ever 
overdosed 
and having 
more than 
four 
bystanders 
present 
independen
tly 
decreases 
the chance 
of calling an 
ambulance  
May decrease 
the likelihood of 
calling an 
ambulance 
because of 
‘diffusion of 
responsibility’ 
 
Tobin et al., 2005. op. 
cit. 
4 Witnesses 
remaining with the 
casualty. 
 
Increase 
or 
decrease 
depending 
on 
response 
 May help 
prevent 
choking or 
provide a 
level of 
sensory 
stimulation 
that 
prevents 
them falling 
too far into 
an 
overdose 
state 
May try 
inappropriate 
measures such 
as slapping or 
shaking 
casualty. 
UK Best et al., 2001. op. 
cit. 
4 Witnesses who 
attempted CPR 
prior to 
ambulance 
arrival.  
Decreas
e 
Not stated Improved 
hospitalisati
on rates 
compared 
to cases 
where it 
was not 
administere
d 
Fears about 
medical care 
and police 
involvement 
(common 
barriers to 
seeking help) 
may be less 
acute among 
those who 
experienced an 
overdose and 
subsequent 
hospitalisation. 
Australia Dietze, P., Cantwell, 
K. & Burgess, S. 
(2002), ‘Bystander 
resuscitation attempts 
at heroin overdose: 
Does it improve 
outcomes?’ Drug and 
Alcohol Dependence, 
67,  
pp. 213–218. 
 
4 Witnesses had 
received 
information on 
how to prevent 
overdose/revive a 
casualty 
 
Decreas
e 
Not stated Not stated Reinforces the 
view that 
providing 
relevant 
information may 
be an effective 
strategy to help 
prevent or 
reduce further 
harm, such as 
related morbidity 
and deaths. 
 Pollini et.al.,  2006. 
op. cit. 
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7 Appendix 2. Protocol and Creation of the Drug Deaths Database in Fife 
 
The template utilised in creating the Fife Drug Deaths (DD) Database was formed from a 
combination of the Centre for Addiction Research and Education Scotland (CARES) 
questionnaire used in the Scottish Executives National Investigation into Drug Related 
Deaths in Scotland in 2003 (2005) and extracts from the Scottish Criminal Drug 
Enforcement Agency (SCDEA) questionnaire. The questionnaire contains the following 
domains: 
 
1. Demographic Characteristics 
2. Life Context and Social Functioning 
3. Criminal Justice Issues and Offending History 
4. Substances Use History 
5. Physical and Psychological Health 
6. Service Provisions 
7. Additional information 
 
The questionnaire is updated when required, and in 2009 a new version (v3.0) of the Fife 
Drug Death Questionnaire was adapted in Fife in 2009. This questionnaire is disseminated 
to all relevant agencies concerned in the provision of care or services to the drug death 
victim (e.g. CJS, NHS Fife Addiction Services and voluntary bodies such as FIRST and 
DAPL). Upon completion, the questionnaire(s) are returned to the committee and 
information pertaining to the domains outlined above is entered into the database. In order 
to adhere to data protection principles, data is anonymised where possible, and coded 
accordingly. The database is securely held on a stand-alone machine and housed within the 
Fife Police Headquarters.  The Drug Death Questionnaire is reproduced at the end of this 
section. 
 
Drug Deaths Database 
 
The main source of information for the current report was the Fife Drugs Death Database 
(EXCEL/SPSS), which holds all data on Drugs Deaths that have occurred within the Fife 
area since 2005.  
 
Data Analysis 
 
Data contained within the Drug Deaths Database is collated by one researcher. The 
process of data collection and analysis broadly involves the following stages:  
 
1. Maintenance the database on a regular basis, entering of new information and 
regular cleansing of existing data 
2. Background research on past/current government directives and relevant literature 
3. Extraction of relevant data pertaining to the seven domains of the questionnaire 
outlines above 
4. Data analysis (via Excel/SPSS) and interpretation/synthesis 
5. Presentation of results 
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Data collection sources  
 
Outlined below are lifestyle domains and sources used in data collection: 
 
Domain 
 
Sources Used 
1. Demographic Characteristics - Sudden Death Report 
 - SCDEA 
 - Fife Drug Death Questionnaire 
  
2.  Life Context and Social Functioning - Sudden Death Report 
 - SCDEA 
 - Social Work Notes, Social Enquiry 
 - Criminal Justice Service Reports 
 - Psychiatric Reports 
 - GP Notes and Correspondences 
 - Fife Drug Death Questionnaire 
  
3. Criminal Justice and Offending - CHS (Criminal History System) 
 - CrimeFile 
 - Sudden Death Report 
 - Post-Mortem/Toxicology Reports 
 - Fife Drug Death Questionnaire 
  
4. Substance Use History - Sudden Death Report 
    And - GP Notes and Correspondences 
5. Physical and Psychological Health - Fife Addiction Service Notes 
 - Psychiatric Reports 
 - Social Work Notes 
 - Fife Drug Death Questionnaire 
  
6. Service Use History All of the above sources 
  
7. Additional Information All of the above sources 
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Context: Step-by-step Guide to Data Collection 
 
Step 1 
 
A suspected Drugs Death occurs in Fife and police attend and carry out investigation into 
the circumstances surrounding the death. The length of the investigation depends upon the 
individual circumstances and can vary from a few days to a number of months. 
 
Step 2 
 
Police inform the ADP, which in turn disseminates the Fife Drug Death Questionnaire 
(Appendix C) to all relevant agencies for completion. At this point, Fife Constabulary also 
request toxicology from the Procurator Fiscal.  
 
Step 3 
 
Agencies check records to see if the individual has accessed their respective services. If the 
individual is known to a particular agency, the Drug Death Questionnaire is completed by 
that agency and returned to Fife Police Headquarters (FPHQ) for the attention of the Drug 
Death Monitoring Group. 
 
Step 4 
 
Police inform NHS Fife of the victim’s GP details and the GP notes are requested on behalf 
of the Drug Deaths Monitoring Group. 
 
Step 5 
 
All questionnaires, case notes and post-mortem/toxicology reports are returned to FPHQ 
where details are entered into the DD Database. This is generally achieved in a six to eight 
week period from the time of death. 
 
Step 6 
 
The Fife Drug Death Monitoring and Strategic Group meet and discuss each death and 
make recommendations. The group meet every eight weeks.  
 
Step 7 
 
All information is finalised in the Fife Drug Death Database.  
 
Step 8 
The Drug Death Researcher, on behalf of the Fife Drug Death Monitoring Group, reports 
each Drug Death, alongside all the detail required of the death to the ISD 
58 
Each individual case is 
discussed at Fife Drug Death 
Monitoring Group and 
recommendations are made 
Required information is 
reported to NHS National 
Services Scotland, Information 
Services Division (ISD) 
Information is finalised within 
the Fife Drug Death Database 
All information is entered into 
the Fife Drug Death Database 
Suspected Drug Death 
(Sudden Death Report, SDR) 
All Fife Drug Death 
Questionnaires, GP Notes and 
Post-mortem/toxicology 
Reports are returned to Fife 
Police Headquarters 
ADP informed 
Fife Drug Death Questionnaire 
disseminated to Agencies 
GP Notes requested via NHS 
Fife 
Police request Post-
mortem/toxicology Report 
Agencies check records and if 
the individual is known the Fife 
Drug Death Questionnaire is 
completed and returned to Fife 
Police Headquarters 
Police investigate Suspected 
Drug Death 
1 EAST CENTRAL SCOTLAND MCN SUSPECTED DRUG DEATH QUESTIONNAIRE 
 
RESTRICTED WHEN COMPLETE 
Page 59 of 82 
Fife Drug Death Questionnaire 
 
(Fife, Forth Valley & Tayside) (Version 1.0) 
 
                             
 
SERVICE:   
 
PERSON COMPLETING:  
 
CONTACT NUMBER OF PERSON COMPLETING:    
 
DATE OF COMPLETION:   
 
NAME OF DECEASED:   
 
CONTENTS: 
 
Section 1 Demographic Characteristics 
Section 2 Life Context and Social Functioning 
Section 3 Criminal Justice and Offending History 
Section 4 Substance Use History 
Section 5 Physical and Psychological Health 
Section 6 Service Contact 
Section 7 Additional Information 
 
GUIDELINES FOR COMPLETION: 
 
 Please complete this questionnaire as best as you can with the information 
available to you about the deceased (including any case notes, referral letters, 
conversations/interviews with the deceased etc.). 
 
 It is unlikely that any one service will be able to complete all the items in the 
questionnaire, therefore don’t worry about marking the ‘unknown’ option. Just 
Centre for Addiction Research 
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complete what you can from each section by marking your answers with an X in 
the left hand column (under the question number). If there is no one answer that 
fits your information, or you have additional information, please put this in the 
free text boxes at the end of the section. 
 
 If you have very little information about the deceased, for example because you 
have had very little contact, or your contact concluded several years ago, please 
provide whatever information that you can in the final free text box (Section 7). 
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(Fife, Forth Valley & Tayside) (Version 1.0) 
QUESTIONNAIRE INFORMATION: 
 
 This questionnaire is used by the Drug Death Groups in Fife, Forth Valley and 
Tayside to better understand Drug Deaths with the aim of saving lives. 
 
 The information reported to us via these questionnaires is collated (with 
information from other sources e.g. GP Notes) and distributed in an anonymised 
and collated annual report for each area. 
 
 The questionnaire was designed by the East Central Scotland Managed Care 
Network Drug Death Sub Group.  It is based on an earlier questionnaire used in 
Fife since 2005, which was originally designed by the Centre for Addiction 
Research and Education Scotland (CARES), University of Dundee.  We would 
also like to acknowledge the Scottish Drug Enforcement Agency, National Drugs 
Database (2006). This questionnaire can also be used to assist in completion of 
the National Drug-Related Deaths Data Collection Form (NHS National Services 
Scotland). 
 
7.1 If you have any questions about this questionnaire please contact: 
Dr Julia Neufeind 
Drug Death Researcher 
Julia.Neufeind@nhs.net 
Or 
Abby Stephenson 
Drug Death Research Assistant 
abbystephenson@nhs.net 
 
Thank you for your cooperation and your help in providing us with this information. 
 
Figure 1:  Drug Death Database Information Input 
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SECTION 1: DEMOGRAPHIC CHARACTERISTICS 
1.1 Date of Birth (day/month/year): 
 
1.2 Community Health Index (CHI) Number: 
 
1.3 GP Details: 
(please specify practice name and address if known) 
 
 
1.4 Gender of Deceased: 
 Male 
 Female 
1.5 Ethnicity: 
 White 
 Black 
 Asian 
 Mixed 
 Other (please specify) 
  
 Unknown 
1.6 Last Known Address: 
1.6.1 Postcode: 
Any Additional Comments/Information for Section 1: 
 
 
DRUG DEATH 
DATABASE 
Toxicology 
(+6-8 weeks) 
DRUG DEATH 
QUESTIONNAIRES 
FROM AGENCIES 
GP Notes Police 
Reports 
SDR (Identify 
Drug Death) 
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SECTION 2: LIFE CONTEXT AND SOCIAL FUNCTIONING 
Life Context at Time of Death 
2.1 What was the deceased’s accommodation in the 6 months before death? 
(can select more than one answer) 
 Owned private accommodation 
 Rented accommodation (please specify private/council if known) 
  
 Homeless accommodation (e.g. shelter) 
 Unstable accommodation (e.g. staying on friend’s couch) 
 Residential rehabilitation 
 Prison 
 Roofless 
 Other (please specify) 
  
 
 Unknown 
 
2.2 What were the deceased’s living arrangements in the 6 months before death? 
(can select more than one answer) 
 Living alone 
 Living with spouse/partner only 
 Living with spouse/partner and other family (e.g. children) 
 Living with friends 
 Living with parents  
 Living with other relatives (please specify) 
  
 
 Living with others (please specify) 
  
 
 Unknown 
 
2.3 What was the deceased’s source of income in the 6 months before death? 
(can select more than one answer) 
 Stable employment with a regular salary 
 Unstable employment (e.g. temporary work) 
 Self-employed 
 State benefits (e.g. jobseekers/incapacity/disability) 
 Illegal income (e.g. criminal activity, benefit fraud) 
 Partner’s or relatives’ income 
 No regular income 
 Other income (please specify) 
 Unknown 
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2.4 Was the deceased in educational/vocational training in the 6 months before 
death? 
 Yes (please specify) 
  
 
 No 
 Other (please specify) 
  
 
 Unknown 
 
Relationships 
2.5 What was the deceased’s relationship at the time of death? 
 Married 
 Co-habiting 
 In a relationship (i.e. couple but not living together) 
 Divorced 
 Separated 
 Widowed 
 Single (please go to question 2.6) 
 Other (please specify) 
  
 
 Unknown (please go to question 2.6) 
 
2.5.1 If the deceased was in a relationship at the time of death, is there evidence to 
suggest that the deceased’s partner had a drug or alcohol problem? 
 Yes (please specify) 
  
 
 No 
 Unknown 
 
2.5.2 Was the deceased’s partner prescribed an opiate substitute? 
 Yes (please specify) 
  
 
 No 
 Unknown 
 
2.5.3 If the deceased was in a relationship at the time of death, is there evidence to 
suggest that there were any difficulties in the relationship? 
 Yes (please specify) 
 No 
 Unknown 
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2.6 Did the deceased have any children? 
(please specify details if known) 
 
DOB/Age Living with the deceased 
Living elsewhere 
with relatives 
Looked after and 
accommodated 
Social Work 
involvement 
(with child) 
      
      
      
      
      
 Unknown 
 
2.7 Did the deceased have any relatives that they were close to? 
 Yes (please specify relationship) 
  
 
 No (please go to question 2.8) 
 Unknown (please go to question 2.8) 
 
2.7.1 Is there evidence to suggest that the deceased’s close relatives had a drug or 
alcohol problem? 
 Yes (please specify) 
  
 
 No 
 Unknown 
 
2.7.2 Was the deceased’s close relative(s) prescribed an opiate substitute?  
 Yes (please specify) 
  
 
 No 
 Unknown 
 
2.7.3 Is there evidence to suggest that there were any difficulties in the deceased’s 
relationship with their close relatives? 
 Yes (please specify) 
  
 
 No 
 Unknown 
 
2.8 Did the deceased have any friends that they were close to? 
 Yes (please specify friendship if known) 
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 No (please go to question 2.9) 
 Unknown (please go to question 2.9) 
 
2.8.1 Is there evidence to suggest that the deceased’s close friend(s) had a drug or 
alcohol problem?  
 Yes (please specify) 
  
 
 No  
 Unknown 
 
2.8.2 Was the deceased’s close friend(s) prescribed an opiate substitute?  
 Yes (please specify) 
  
 
 No 
 Unknown 
 
2.8.3 Is there evidence to suggest that there were any difficulties in the deceased’s 
relationship with their friend(s)? 
 Yes (please specify) 
  
 
 No 
 Unknown 
 
Social History 
2.9 As a child/young person, were the deceased’s parents 
divorced/separated/deceased? 
 Yes (please specify) 
  
 
 No 
 Unknown 
 
2.1
0 
Was the deceased in regular contact with parents as a child/young person? 
 Yes (please specify) 
 
 
 
 No (please specify) 
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 Unknown 
 
2.1
1 Was the deceased’s residential situation stable as a child/young person? 
 Yes 
 No (please specify) 
  
 
 Unknown 
 
2.1
2 Was the deceased’s schooling situation stable as a child/young person? 
 Yes 
 No (please specify) 
  
 
 Unknown 
 
2.1
3 
Were there any other adverse events of note in the deceased’s 
childhood/adolescence? 
 Yes (please specify details if known) 
  
 
 No 
 Unknown 
 
2.1
4 At what age did the deceased leave secondary school? 
 Age 
 Unknown 
 
2.1
5 Did the deceased leave school with qualifications? 
 Yes 
 No 
 Unknown 
 
2.1
6 What did the deceased do immediately after leaving secondary school? 
 Further education 
 Employment 
 Vocational training/apprenticeship 
 Unemployed 
 Other (please specify) 
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 Unknown 
 
2.1
7 
Is there any indication of domestic abuse? 
 Yes (perpetrator of domestic abuse – recent, in the six months prior to death) 
 Yes (perpetrator of domestic abuse – in the past) 
 Yes (suffered domestic abuse – recent, in the six months prior to death) 
 Yes (suffered domestic abuse – in the past) 
 No 
 Unknown 
 
2.1
8 Is there any indication of sexual abuse? 
 Yes (perpetrator of sexual abuse – recent, in the six months prior to death) 
 Yes (perpetrator of sexual abuse – in the past) 
 Yes (suffered sexual abuse – recent, in the six months prior to death) 
 Yes (suffered sexual abuse – in the past) 
 No 
 Unknown 
 
Any Additional Comments/Information for Section 2: 
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SECTION 3: CRIMINAL JUSTICE AND OFFENDING HISTORY 
3.1 Does the deceased have a criminal history? 
(including arrests) 
 Yes  
 No (please go to section 4) 
 Unknown (please go to section 4) 
 
3.2 What is the deceased SCRO/PNC number? 
  
 Unknown 
 
3.3 Please specify details of the deceased’s last six arrests/stays in police 
custody: 
(beginning with the most recent) 
 
Date (entered 
custody) 
Date (released 
from custody) 
Charge(s) 
/offence(s) 
Disposal (e.g. 
release no 
charge, fine 
etc.) 
Did deceased 
disclose 
addiction? 
Was 
medication 
administered? 
(please 
specify) 
3.3.1 
      
3.3.2 
      
3.3.3 
      
3.3.4 
      
3.3.5 
      
3.3.6 
      
 Unknown 
 
3.4 Has the deceased ever been in prison? 
 Yes  
 No 
 Unknown 
 
3.4.1 How many times has the deceased been in prison? 
(please specify dates for the last six stays below if known) 
  
 Unknown 
 
3.4.2 Date(s) entered custody Date(s) released from custody 
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 Unknown 
 
3.5 Please specify details of most recent stay in prison: 
3.5.1 Prison of release or prison of main stay if different from release 
  
 Unknown 
 
3.5.2 Charge(s)/offence(s) 
  
 Unknown 
 
3.5.3 If short stay, was the deceased entered into the short stay prisoners protocol? 
 Yes 
 No 
 Unknown 
 
3.5.4 Did the deceased receive over dose prevention training prior to release? 
 Yes 
 No 
 Unknown 
 
3.5.5 Was take home Narcan given to the deceased on release? 
 Yes 
 No 
 Unknown 
 
Any Additional Comments/Information for Section 3: 
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SECTION 4: SUBSTANCE USE HISTORY 
Drug Using and Injecting Behaviour  
4.1 At what age did the deceased begin using drugs? 
  
 Unknown 
 
4.2 Has the deceased ever injected? 
 Yes 
 No 
 Unknown 
 
4.3 At what age did the deceased begin to inject? 
  
 Unknown 
 
4.4 Did the deceased suffer from problematic alcohol use currently or in the past?  
(can select more than one answer) 
 Yes – at the time of death 
 Yes – in the past 
 No (please go to question 5.5) 
 Unknown (please go to question 5.5) 
  
4.5 Has the deceased ever received treatment for problematic alcohol abuse?  
 In patient detox 
 Community based detox 
 Pharmacotherapy 
 Talk based therapy (individual/group) 
 Other (please specify) 
  
 
 No 
 Unknown 
 
4.6 What non-prescribed substances are you aware that the deceased used 
currently or in the past:  
(please specify details if known) 
 
Drug Ever Used 
Age 
Started 
Current 
Use 
Usual Route 
(e.g. inject, oral, 
smoke etc.) 
Any Other 
Information (e.g. 
amounts recently 
used) 
 
Alcohol      
 
Amphetamines      
 
Cannabis      
 
Cocaine      
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Crack Cocaine      
 
Dihydrocodeine      
 
Diazepam      
 
Ecstasy      
 
Heroin/morphine      
 
Methadone      
 
Temazepam      
 
Other (please specify) 
 
 
   
  
 
 
   
  
 
 
   
  
 Unknown 
 
N.B. For prescribed medication please see Section 5 
 
Drug Treatment (Current) 
4.7 Was the deceased on a waiting list for an opiate substitute? 
 Yes (please specify) 
  
 
 No 
 Unknown 
  
4.8 Was the deceased prescribed an opiate substitute? 
 Methadone 
 Suboxone 
 Benzodiazepine 
 Buprenorphine 
 Dihydrocodeine 
 Other (please specify) 
  
 
 No (please go to question 4.9)  
 Unknown (please go to question 4.9) 
  
 
4.8.1 What date did the treatment episode begin? 
  
 Unknown 
 
4.8.2 What date was the prescription last dispensed? 
  
 Unknown 
 
4.8.3 How many times was the prescription dispensed per week? 
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 Unknown 
 
4.8.4 How many doses per week? 
  
 Unknown 
 
4.8.5 Was consumption supervised? 
 Yes (Daily) 
 Yes (6/7 days per week) 
 Other (please specify) 
  
 
 No 
 Unknown 
 
4.8.6 Did the deceased regularly miss the collection of their substitute medication? 
(please specify how many times in the last month if known) 
 Yes  
  
 No 
 Unknown 
 
4.8.7 What was the current daily dose? 
  
 Unknown 
 
Drug Testing 
4.9 How many times did the deceased have a drug test in the last 12 months? 
  
 Unknown 
 
4.9.1 Please specify date of the most recent drug test: 
  
 Unknown 
 
4.9.2 Please specify details of the most recent drug test 
 Drug Tested Positive 
 Amphetamines 
 
 Cannabis 
 
 Cocaine 
 
 Dihydrocodeine 
 
 Diazepam 
 
 Ecstasy 
 
 Heroin/morphine 
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 Methadone 
 
 Temazepam 
 
 Other (please specify) 
 
  
 
  
 Unknown 
 
4.1
0 
How many times was the deceased breathalysed for alcohol misuse in the last 
12 months? 
  
 Unknown 
 
4.10.1 Please specify date of the deceased’s last breathalyser:  
  
 Unknown 
 
4.10.2 Please specify result of the deceased’s last breathalyser: 
  
 Unknown 
 
Overdose History 
4.1
0 Has the deceased ever overdosed? 
 Yes 
 No (please go to section 5) 
 Unknown (please go to section 5) 
 
4.10.1 Please specify details of the deceased’s overdose history: 
 
Date Drug Intentional Accidental Unknown 
      
      
      
      
      
 
4.1
1 Has the deceased ever received over dose training? 
 Yes 
 No 
 Unknown  
 
Any Additional Comments/Information for Section 4: 
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SECTION 5:  PHYSICAL AND PSYCHOLOGICAL HEALTH  
Physical Health 
5.1 Was the deceased suffering from a long term physical illness currently or in the 
past? (please specify details if known) 
 
Condition Past Current 
 
Cancer 
  
 
Cardiac Condition 
  
 
Diabetes 
  
 
DVT 
  
 
Epilepsy 
  
 
Hepatitis C 
  
 
HIV/AIDS 
  
 
Liver Disease 
  
 
Respiratory Condition 
  
 
Other (please specify) 
    
    
 No  
 Unknown  
 
5.2 Was the deceased prescribed medication currently e.g. analgesics, anti-
depressants, benzodiazepines etc? 
(please specify details if known) 
 
Medication Current Prescription Prescribed for: 
    
    
    
    
 
Other (please specify) 
    
    
 Unknown 
 
Mental Health 
5.3 Was the deceased suffering from a mental health problem currently or in the 
past?  
(please specify details if known) 
 
Condition Past Current 
 
Anxiety 
  
 
Bi-polar Disorder 
  
 
Depression 
  
 
Personality Disorder 
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Post Traumatic Stress 
Disorder   
 
Schizophrenia 
  
 
Schizoaffective Disorder 
  
 
Other (please specify) 
    
    
    
 No  
 Unknown 
 
5.4 Was the deceased in contact with mental health services at the time of death? 
 Yes (please specify) 
  
 
 No 
 Unknown  
 
Self Harm History 
5.5 Has the deceased ever self harmed? 
(exclude overdoses previously recorded) 
 Yes 
 No (please go to question 5.6) 
 Unknown (please go to question 5.6) 
 
5.5.1 How many times did the deceased self harm? 
  
 Unknown 
 
5.5.2 Please specify the date of the last incidence of self harm: 
  
 Unknown 
 
Significant Events 
5.6 Have any significant events occurred in the deceased’s life recently?  
(In the six month prior to death) 
 Accident (please specify details including dates if known) 
  
 
 Assault (please specify details including dates if known) 
  
 
 Bereavement (please specify details including dates if known) 
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 Child custody issues (please specify) 
  
 
 Other (please specify) 
  
 
 Unknown 
 
5.7 Have any significant events recently occurred involving the deceased’s 
partner, close relative(s) or close friend(s)? 
 
Significant event Partner Close Relative(s) Close Friend(s) 
 
Recently diagnosed 
physical illness    
 
Recently diagnosed 
mental illness    
 
Recent injury 
 
   
 
Other (please specify) 
     
     
     
 Unknown 
 
Any Additional Comments/Information for Section 5: 
 
 
 
  78 
 
SECTION 6:  SERVICE CONTACT  
Please complete as much of this section as you can if the deceased had any 
contact with your service 
6.1 Who first referred the deceased to your service? 
 Criminal Justice 
 GP 
 Mental Health 
 Self  
 Social work 
 Other (please specify) 
  
 
 Unknown 
 
6.2 Please specify the date(s) of referral and discharge for the past twelve months: 
 Referral Date(s) Discharge Date(s) 
   
   
   
   
   
 
6.3 Did the deceased make contact/attend the first appointment offered? 
 Yes 
 CNA 
 DNA 
 Unknown 
  
 
6.4 Was attendance at appointments mandatory? 
 Yes 
 No 
 Unknown 
 
6.5 Please specify the deceased’s attendance at appointments: 
 Regularly attended 
 Poor attendance 
 DNA all appointments offered 
 Telephone contact 
 Other (please specify) 
  
 
 Unknown 
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6.6 Please specify the content of treatment episodes: 
 Other (please specify) 
  
 
 Unknown 
 
6.7 Please specify the main issues addressed during your contact with the 
deceased: 
 Treatment/support for addiction 
 Harm reduction 
 Needle exchange  
 Mental health issues  
 Housing support 
 Child custody/maintenance  
 Issues in deceased childhood/adolescence  
 Other (please specify) 
  
 
 Unknown 
 
6.8 Please specify the main reason for discharge: 
 Treatment complete 
 Support no longer required 
 Non-compliance 
 DNA 
 Other (please specify) 
  
 
 Unknown 
 
6.9 Did you refer the deceased on to any other service?  
(please specify details if known) 
 Service: 
  
 Date of Onwards Referral: 
  
 Main reason for referring on (e.g. mandated/discharge protocol): 
  
 No 
 Unknown 
 
6.1
0 
Are you aware of any other services the deceased was accessing currently or 
had accessed in the past? 
(please specify details if known) 
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Service Past Current 
    
    
    
 Unknown 
 
6.1
1 Are you aware if the deceased was waiting to be seen by any other services? 
 Yes (please specify) 
  
 
 No 
 Unknown 
 
Any Additional Comments/Information for Section 6: 
 
 
 
 
SECTION 7: ADDITIONAL INFORMATION 
7.1 Please specify any additional/other information about the deceased in the free 
text box below: 
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8 Appendix 3. A Case Vignette of a Typical Drug Death Victim in Fife 2009 
 
The average Drug Death victim from Fife would be a White Caucasian 34 year old male 
who lived in central Fife. He would have started his substance misuse at the age of 16 
years; around that time he would also have left school. He would have gained 
employment or started an apprenticeship as a labourer. His childhood would have been 
disrupted; he would have had a family history of psychiatric difficulties and/or substance 
misuse. He may have suffered physical/sexual abuse and/or spent some time in care. 
 
He would have proceeded to misuse a cocktail of drugs and approximately 4 years after 
leaving school later he would have started taking heroin. He would have started 
injecting at around 24 years of age. He would have maintained meaningful and close 
relationships with his friends and family members throughout his life. He would have 
had children; however, they would not have lived with him and he would have lost 
custody of them. 
 
He would have been known to at least 2 services, intermittently, including his GP and 
criminal justice services in Fife during the 5 years prior to his death. In this time he 
would have been misusing several types of substances including heroin, 
benzodiazepines (prescribed and/ or non-prescribed), alcohol and latterly methadone. 
He would also have encountered at least one complex episode of a co-morbid 
psychiatric or physical health problem with or without instances of drugs overdose 
and/or self-harm. He would also have experienced other life events, such as 
bereavement and the loss of a close relationship. He would have criminal record and 
have served a prison sentence some point during his life.   
 
In the six months before his death he would have been arrested at least once. He would 
have committed crimes linked to his drug use and have outstanding charges/court 
cases at the time of his death, for crimes such as shoplifting or driving whilst under the 
influence of a controlled substance. At the time of his death, he would be unemployed, 
living alone or living with other adults and would not have changed accommodation type 
during those 6 months. He would have been classed as single, but may have been in a 
volatile, on/off relationship at this time. He would have been close to friends and family 
members and so would not have been socially isolated. During this time he would have 
been known to GP and Fife NHS Addiction Services but would not have 
sought/received pharmacological treatment for his drug dependency. During this time, 
he would be misusing a cocktail of illicit and prescribed substances.  
 
On the day of this death he would have purchased at least one ‘tenner’ bag of heroin 
alongside alcohol and benzodiazepines. He would have shared these amongst friends/ 
co-users and injected in the presence of them. He would have died in the presence of 
others and would have been believed to be sleeping and any attempts to revive him 
would therefore have been delayed. Any means of formal resuscitation such as CPR, if 
attempted at all, would have been only partially conducted. He would have died at his 
resident home address, or in close proximity thereof.  
 
  82 
At post mortem his blood sample would have revealed a cocktail of depressants such 
as morphine, benzodiazepines, alcohol and/or methadone. His cause of death would 
most likely have been classed as “Adverse Effects of Heroin”. 
